

FILE 'HOME' ENTERED AT 17:03:06 ON 15 AUG 2008

=> file medline biosis polymer embase  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 17:03:41 ON 15 AUG 2008

FILE 'BIOSIS' ENTERED AT 17:03:41 ON 15 AUG 2008  
Copyright (c) 2008 The Thomson Corporation

FILE 'APOLLIT' ENTERED AT 17:03:41 ON 15 AUG 2008  
COPYRIGHT (c) 2008 FIZ Karlsruhe

FILE 'BABS' ENTERED AT 17:03:41 ON 15 AUG 2008  
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften  
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'CAPLUS' ENTERED AT 17:03:41 ON 15 AUG 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CBNB' ENTERED AT 17:03:41 ON 15 AUG 2008  
COPYRIGHT (c) 2008 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 17:03:41 ON 15 AUG 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 17:03:41 ON 15 AUG 2008  
Compendex Compilation and Indexing (C) 2008  
Elsevier Engineering Information Inc (EEI). All rights reserved.  
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'DISSABS' ENTERED AT 17:03:41 ON 15 AUG 2008  
COPYRIGHT (C) 2008 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'EMA' ENTERED AT 17:03:41 ON 15 AUG 2008  
COPYRIGHT (C) 2008 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 17:03:41 ON 15 AUG 2008  
COPYRIGHT (C) 2008 IFI CLAIMS(R) Patent Services (IFI)

FILE 'NTIS' ENTERED AT 17:03:41 ON 15 AUG 2008  
Compiled and distributed by the NTIS, U.S. Department of Commerce.  
It contains copyrighted material.  
All rights reserved. (2008)

FILE 'PASCAL' ENTERED AT 17:03:41 ON 15 AUG 2008  
Any reproduction or dissemination in part or in full,  
by means of any process and on any support whatsoever  
is prohibited without the prior written agreement of INIST-CNRS.  
COPYRIGHT (C) 2008 INIST-CNRS. All rights reserved.

FILE 'PROMT' ENTERED AT 17:03:41 ON 15 AUG 2008  
COPYRIGHT (C) 2008 Gale Group. All rights reserved.

FILE 'RAPRA' ENTERED AT 17:03:41 ON 15 AUG 2008  
COPYRIGHT (C) 2008 RAPRA Technology Ltd.

FILE 'SCISEARCH' ENTERED AT 17:03:41 ON 15 AUG 2008  
Copyright (c) 2008 The Thomson Corporation

FILE 'TEXTILETECH' ENTERED AT 17:03:41 ON 15 AUG 2008  
COPYRIGHT (C) 2008 Inst. of Textile Technology

FILE 'USPATFULL' ENTERED AT 17:03:41 ON 15 AUG 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:03:41 ON 15 AUG 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:03:41 ON 15 AUG 2008  
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ACCESS NOT AUTHORIZED

FILE 'WPIFV' ENTERED AT 17:03:41 ON 15 AUG 2008  
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'WPINDEX' ENTERED AT 17:03:41 ON 15 AUG 2008  
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'WSCA' ENTERED AT 17:03:41 ON 15 AUG 2008  
COPYRIGHT (C) 2008 PAINT RESEARCH

FILE 'WTEXTILES' ENTERED AT 17:03:41 ON 15 AUG 2008  
COPYRIGHT (C) 2008 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EMBASE' ENTERED AT 17:03:41 ON 15 AUG 2008  
Copyright (c) 2008 Elsevier B.V. All rights reserved.

```
=> s topoisomerase(a)II(a)poison
L1      0 TOPOISOMERSE(A) II(A) POISON

=> s topoisomerase(a)II(a)poison
L2      1540 TOPOISOMERASE(A) II(A) POISON

=> s l2 and (dioxypiperazine or piperazinedione)
L3      21 L2 AND (DIOXYPIPERAZINE OR PIPERAZINEDIONE)

=> dis l3 1-21 bib abs
```

```
L3      ANSWER 1 OF 21      MEDLINE on STN
AN      2007557753      MEDLINE
DN      PubMed ID: 17622580
TI      A mouse model for studying the interaction of bisdioxopiperazines with
topoisomerase IIalpha in vivo.
AU      Grauslund Morten; Thougard Annemette Vinding; Fuchtbauer Annette; Hofland
Kenneth Francis; Hjorth Peter Hansen; Jensen Peter B; Sehested Maxwell;
Fuchtbauer Ernst-Martin; Jensen Lars H
CS      Experimental Pathology Unit, Department of Pathology, Rigshospitalet afs.
3731, Biocenter, Bygning 2, 3 sal., Ole Maaloes vej 5, DK-2100 Copenhagen
O, Denmark.
SO      Molecular pharmacology, (2007 Oct) Vol. 72, No. 4, pp. 1003-14.
Electronic Publication: 2007-07-10.
Journal code: 0035623. ISSN: 0026-895X.
CY      United States
```

DT Journal; Article; (JOURNAL ARTICLE)  
(RESEARCH SUPPORT, NON-U.S. GOV'T)

LA English

FS Priority Journals

EM 200711

ED Entered STN: 20 Sep 2007  
Last Updated on STN: 8 Dec 2007  
Entered Medline: 27 Nov 2007

AB The bisdioxopiperazines such as (+)-(S)-4,4'-propylenedi-2,6-piperazinedione (dexrazoxane; ICRF-187), 1,2-bis(3,5-dioxopiperazin-1-yl)ethane (ICRF-154), and 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione (ICRF-193) are agents that inhibit eukaryotic topoisomerase II, whereas their ring-opened hydrolysis products are strong iron chelator. The clinically approved analog ICRF-187 is a pharmacological modulator of topoisomerase II poisons such as etoposide in preclinical animal models. ICRF-187 is also used to protect against anthracycline-induced cardiomyopathy and has recently been approved as an antidote for alleviating tissue damage and necrosis after accidental anthracycline extravasation. This dual modality of bisdioxopiperazines, including ICRF-187, raises the question of whether their pharmacological in vivo effects are mediated through interaction with topoisomerase II or via their intracellular iron chelating activity. In an attempt to distinguish between these possibilities, we here present a transgenic mouse model aimed at identifying the contribution of topoisomerase IIalpha to the effects of bisdioxopiperazines. A tyrosine 165 to serine mutation (Y165S) in topoisomerase IIalpha, demonstrated previously to render the human ortholog of this enzyme highly resistant toward bisdioxopiperazines, was introduced at the TOP2A locus in mouse embryonic stem cells by targeted homologous recombination. These cells were used for the generation of transgenic TOP2A(Y165S/+) mice, which were demonstrated to be resistant toward the general toxicity of both ICRF-187 and ICRF-193. Hematological measurements indicate that this is most likely caused by a decreased ability of these agents to induce myelosuppression in TOP2A(Y165S/+) mice, highlighting the role of topoisomerase IIalpha in this process. The biological and pharmacological implications of these findings are discussed, and areas for further investigations are proposed.

L3 ANSWER 2 OF 21 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN  
AN 2008:312487 BIOSIS  
DN PREV200800316670  
TI A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase II alpha in vivo.

AU Grauslund, Morten; Thougard, Annemette Vinding; Fuechtbauer, Annette; Hofland, Kenneth Francis; Hjorth, Peter Hansen; Jensen, Peter B.; Sehested, Maxwell; Fuechtbauer, Ernst-Martin; Jensen, Lars H. [Reprint Author]

CS Rigshosp, Dept Pathol, Expt Pathol Unit, Bioctr, Bygning 2,3 Sal,Ole Maaloes Vej 5, DK-2100 Copenhagen O, Denmark  
lhj@topotarget.com

SO Molecular Pharmacology, (OCT 2007) Vol. 72, No. 4, pp. 1003-1014.  
<http://www.molpharm.org>.  
CODEN: MOPMA3. ISSN: 0026-895X.

DT Article

LA English

ED Entered STN: 21 May 2008  
Last Updated on STN: 21 May 2008

AB The bisdioxopiperazines such as (+)-(S)-4,4'-propylenedi-2,6-piperazinedione (dexrazoxane; ICRF-187), 1,2-bis(3,5-dioxopiperazin-1-yl)ethane (ICRF-154), and 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione (ICRF-193) are agents that

inhibit eukaryotic topoisomerase II, whereas their ring-opened hydrolysis products are strong iron chelator. The clinically approved analog ICRF-187 is a pharmacological modulator of topoisomerase II poisons such as etoposide in preclinical animal models. ICRF-187 is also used to protect against anthracycline-induced cardiomyopathy and has recently been approved as an antidote for alleviating tissue damage and necrosis after accidental anthracycline extravasation. This dual modality of bisdioxopiperazines, including ICRF-187, raises the question of whether their pharmacological in vivo effects are mediated through interaction with topoisomerase II or via their intracellular iron chelating activity. In an attempt to distinguish between these possibilities, we here present a transgenic mouse model aimed at identifying the contribution of topoisomerase II alpha to the effects of bisdioxopiperazines. A tyrosine 165 to serine mutation (Y165S) in topoisomerase II alpha, demonstrated previously to render the human ortholog of this enzyme highly resistant toward bisdioxopiperazines, was introduced at the TOP2A locus in mouse embryonic stem cells by targeted homologous recombination. These cells were used for the generation of transgenic TOP2A(Y165S/+) mice, which were demonstrated to be resistant toward the general toxicity of both ICRF-187 and ICRF-193. Hematological measurements indicate that this is most likely caused by a decreased ability of these agents to induce myelosuppression in TOP2A(Y165S/+) mice, highlighting the role of topoisomerase II alpha in this process. The biological and pharmacological implications of these findings are discussed, and areas for further investigations are proposed.

L3 ANSWER 3 OF 21 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN  
AN 2001:435706 BIOSIS  
DN PREV200100435706  
TI Topoisomerase II poison and  
bis-dioxopiperazine derivative combination therapy.  
AU Jensen, Peter Buhl [Inventor, Reprint author]; Sehested, Maxwell  
[Inventor]  
CS Farum, Denmark  
ASSIGNEE: Topo Target ApS, Copenhagen, Denmark  
PI US 6265385 20010724  
SO Official Gazette of the United States Patent and Trademark Office Patents,  
(July 24, 2001) Vol. 1248, No. 4. e-file.  
CODEN: OGPUPE7. ISSN: 0098-1133.  
DT Patent  
LA English  
ED Entered STN: 12 Sep 2001  
Last Updated on STN: 22 Feb 2002  
AB The present invention relates to a method for selectively killing tumor or  
metastatic cells within a defined compartment of the organism of a large  
mammal, in particular a human, said method comprising administering to a  
mammal an effective tumor--or metastasis-killing amount of a  
topoisomerase II poison except doxorubicin,  
and protecting non-tumorous tissue of the mammal against the toxic action  
of the topoisomerase II poison by  
administration of a bis-dioxypiperazine compound. In  
particular, the invention relates to a pharmaceutical kit for selectively  
killing tumor or metastatic cells within the central nervous system in a  
large mammal, in particular a human, said kit comprising: a) a dosage unit  
of a bis-dioxypiperazine and a pharmaceutically acceptable  
carrier, and b) a dosage unit of topoisomerase II  
poisons except doxorubicin and a pharmaceutically acceptable  
carrier.

L3 ANSWER 4 OF 21 BABS COPYRIGHT 2008 BEILSTEIN MDL on STN  
AN 6710431 BABS

TI A mouse model for studying the interaction of bisdioxopiperazines with  
 topoisomerase II $\alpha$  in vivo  
 AU Grauslund, Morten; Thougaard, Annemette Vinding; Fuechtbauer, Annette;  
 Hofland, Kenneth Francis; Hjorth, Peter Hansen; Jensen, Peter B.;  
 Sehested, Maxwell; Fuechtbauer, Ernst-Martin; Jensen, Lars H.  
 SO Mol. Pharmacol. (2007), 72(4), 1003 - 1014  
 CODEN: MOPMA3  
 DT Journal  
 AN 6710431 BABS  
 AB The bisdioxopiperazines such as (+)-(S)-4,4'-propylenedi-2,6-  
 piperazinedione (dexrazoxane; ICRF-187), 1,2-bis(3,5-  
 dioxopiperazin-1-yl)ethane (ICRF-154), and 4,4'-(1,2-dimethyl-1,2-  
 ethanediyl)bis-2,6-piperazinedione (ICRF-193) are agents that  
 inhibit eukaryotic topoisomerase II, whereas their ring-opened hydrolysis  
 products are strong iron chelator. The clinically approved analog ICRF-187  
 is a pharmacological modulator of topoisomerase II  
 poisons such as etoposide in preclinical animal models. ICRF-187  
 is also used to protect against anthracycline-induced cardiomyopathy and  
 has recently been approved as an antidote for alleviating tissue damage  
 and necrosis after accidental anthracycline extravasation. This dual  
 modality of bisdioxopiperazines, including ICRF-187, raises the question  
 of whether their pharmacological in vivo effects are mediated through  
 interaction with topoisomerase II or via their intracellular iron  
 chelating activity. In an attempt to distinguish between these  
 possibilities, we here present a transgenic mouse model aimed at  
 identifying the contribution of topoisomerase II $\alpha$  to the effects of  
 bisdioxopiperazines. A tyrosine 165 to serine mutation (Y165S) in  
 topoisomerase II $\alpha$ , demonstrated previously to render the human  
 ortholog of this enzyme highly resistant toward bisdioxopiperazines, was  
 introduced at the TOP2A locus in mouse embryonic stem cells by targeted  
 homologous recombination. These cells were used for the generation of  
 transgenic TOP2A Y165S/+ mice, which were demonstrated to be resistant  
 toward the general toxicity of both ICRF-187 and ICRF-193. Hematological  
 measurements indicate that this is most likely caused by a decreased  
 ability of these agents to induce myelosuppression in TOP2AY165S/+ mice,  
 highlighting the role of topoisomerase II $\alpha$  in this process. The  
 biological and pharmacological implications of these findings are  
 discussed, and areas for further investigations are proposed.

L3 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:1121923 CAPLUS  
 DN 147:479990  
 TI A mouse model for studying the interaction of bisdioxopiperazines with  
 topoisomerase II $\alpha$  in vivo  
 AU Grauslund, Morten; Thougaard, Annemette Vinding; Fuchtbauer, Annette;  
 Hofland, Kenneth Francjs; Hjorth, Peter Hansen; Jensen, Peter B.;  
 Sehested, Maxwell; Fuchtbauer, Ernst-Martin; Jensen, Lars H.  
 CS Experimental Pathology Unit, Department of Pathology, Copenhagen  
 University Hospital, Copenhagen, Den.  
 SO Molecular Pharmacology (2007), 72(4), 1003-1014  
 CODEN: MOPMA3; ISSN: 0026-895X  
 PB American Society for Pharmacology and Experimental Therapeutics  
 DT Journal  
 LA English  
 AB The bisdioxopiperazines such as (+)-(S)-4,4'-propylenedi-2,6-  
 piperazinedione (dexrazoxane; ICRF-187), 1,2-bis(3,5-  
 dioxopiperazin-1-yl)ethane (ICRF-154), and 4,4'-(1,2-dimethyl-1,2-  
 ethanediyl)bis-2,6-piperazinedione (ICRF-193) are agents that  
 inhibit eukaryotic topoisomerase II, whereas their ring-opened hydrolysis  
 products are strong iron chelator. The clin. approved analog ICRF-187 is  
 a pharmacol. modulator of topoisomerase II

poisons such as etoposide in preclin. animal models. ICRF-187 is also used to protect against anthracycline-induced cardiomyopathy and has recently been approved as an antidote for alleviating tissue damage and necrosis after accidental anthracycline extravasation. This dual modality of bisdioxopiperazines, including ICRF-187, raises the question of whether their pharmacol. in vivo effects are mediated through interaction with topoisomerase II or via their intracellular iron chelating activity. In an attempt to distinguish between these possibilities, the authors here present a transgenic mouse model aimed at identifying the contribution of topoisomerase II $\alpha$  to the effects of bisdioxopiperazines. A tyrosine 165 to serine mutation (Y165S) in topoisomerase II $\alpha$ , demonstrated previously to render the human ortholog of this enzyme highly resistant toward bisdioxopiperazines, was introduced at the TOP2A locus in mouse embryonic stem cells by targeted homologous recombination. These cells were used for the generation of transgenic TOP2AY165S/+ mice, which were demonstrated to be resistant toward the general toxicity of both ICRF-187 and ICRF-193. Hematol. measurements indicate that this is most likely caused by a decreased ability of these agents to induce myelosuppression in TOP2AY165S/+ mice, highlighting the role of topoisomerase II $\alpha$  in this process. The biol. and pharmacol. implications of these findings are discussed, and areas for further investigations are proposed.

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1004605 CAPLUS

DN 143:279366

TI Cancer treatment with topoisomerase II inhibitor, a bis-dioxopiperazine and radiation

IN Hofland, Kenneth; Sehested, Maxwell; Kristjansen, Paul; Thougard, Annemette; Jensen, Peter Buhl

PA Topotarget A/S, Den.

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005084754	A2	20050915	WO 2005-IB670	20050302
	WO 2005084754	A3	20060526		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005219034	A1	20050915	AU 2005-219034	20050302
	CA 2557857	A1	20050915	CA 2005-2557857	20050302
	EP 1720612	A2	20061115	EP 2005-708755	20050302
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	JP 2007527428	T	20070927	JP 2007-501380	20050302
	US 20070185124	A1	20070809	US 2007-591847	20070109
PRAI	GB 2004-4675	A	20040302		

WO 2005-IB670 W 20050302

AB The present invention relates to a method of treatment of a tumor cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane, wherein said subject is further treated with radiation.

L3 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:556108 CAPLUS

DN 127:145175

OREF 127:27889a

TI Topoisomerase II poison and bis-dioxypiperazine derivative combination therapy

IN Jensen, Peter Buhl; Sehested, Maxwell

PA Jensen, Peter Buhl, Den.; Sehested, Maxwell

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9725044	A1	19970717	WO 1997-DK13	19970110
	W:	AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	CA 2242406	A1	19970717	CA 1997-2242406	19970110
	AU 9713677	A	19970801	AU 1997-13677	19970110
	EP 874630	A1	19981104	EP 1997-900205	19970110
	EP 874630	B1	20030820		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	AT 247468	T	20030915	AT 1997-900205	19970110
	PT 874630	T	20040130	PT 1997-900205	19970110
	ES 2205164	T3	20040501	ES 1997-900205	19970110
	US 6265385	B1	20010724	US 1999-101499	19990308
PRAI	DK 1996-22	A	19960111		
	US 1996-603105	A	19960220		
	WO 1997-DK13	W	19970110		

AB The present invention relates to a method for selectively killing tumor or metastatic cells within a defined compartment of the organism of a large mammal, in particular a human, said method comprising administering to a mammal an effective tumor- or metastasis-killing amount of a topoisomerase II poison except doxorubicin, and protecting non-tumorous tissue of the mammal against the toxic action of the topoisomerase II poison by administration of a bis-dioxypiperazine compound. In particular, the invention relates to a pharmaceutical kit for selectively killing tumor or metastatic cells within the central nervous system of a large mammal, in particular a human, said kit comprising: a) a dosage unit of a bis-dioxypiperazine and a pharmaceutically acceptable carrier, and b) a dosage unit of topoisomerase II poisons except doxorubicin and a pharmaceutically acceptable carrier.

L3 ANSWER 8 OF 21 IFIPAT COPYRIGHT 2008 IFI on STN

AN 11535037 IFIPAT;IFIUDB;IFICDB  
 TI Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation  
 INF Hofland; Kenneth, Copenhagen, DK  
 Sehested; Maxwell, Copenhagen, DK  
 Kristjansen; Paul, Copenhagen, DK  
 Thougard; Annenette, Copenhagen, DK  
 Jensen; Peter Buhl, Copenhagen, DK  
 IN Hofland Kenneth (DK); Jensen Peter Buhl (DK); Kristjansen Paul (DK);  
 Sehested Maxwell (DK); Thougard Annenette (DK)  
 PAF Unassigned  
 PA Unassigned Or Assigned To Individual (68000)  
 PPA Topotarget A S DK (Probable)  
 AG NIXON & VANDERHYE, PC, 901 NORTH GLEBE ROAD, 11TH FLOOR, ARLINGTON, VA,  
 22203, US  
 PI US 20070185124 A1 20070809  
 AI US 2005-591847 20050302  
 WO 2005-IB670 20050302  
 20070109 PCT 371 date  
 20070109 PCT 102(e) date  
 PRAI GB 2004-46751 20040302  
 FI US 20070185124 20070809  
 DT Utility; Patent Application - First Publication  
 FS CHEMICAL  
 APPLICATION  
 ED Entered STN: 10 Aug 2007  
 Last Updated on STN: 13 Sep 2007  
 CLMN 10  
 AB The present invention relates to a method of treatment of a tumour cell  
 which comprises administering to a subject in need of treatment an  
 effective amount of a topoisomerase-II poison  
 , e.g. etoposide, in combination with a bis-dioxypiperazine,  
 e.g. dexrazoxane wherein said subject is further treated with radiation.  
 CLMN 10  
 L3 ANSWER 9 OF 21 IFIPAT COPYRIGHT 2008 IFI on STN  
 AN 03547524 IFIPAT;IFIUDB;IFICDB  
 TI TOPOISOMERASE II POISON AND  
 BIS-DIOXOPIPERAZINE DERIVATIVE COMBINATION THERAPY; SELECTIVELY KILLING  
 TUMOR OR METASTATIC CELLS WITHIN A DEFINED COMPARTMENT OF A HUMAN;  
 TOPOISOMERASE II POISON IS ETOPOSIDE OR  
 TENIPOSIDE AND WHERE SAID BIS-DIOXOPIPERAZINE IS (+)-1,2-BIS(3,5-  
 DIOXOPIPERAZINYL-1-YL)PROPANE  
 INF Jensen; Peter Buhl, Farum, DK  
 Sehested; Maxwell, Kobenhavn O, DK  
 IN Jensen Peter Buhl (DK); Sehested Maxwell (DK)  
 PAF Topo Target ApS, Copenhagen, DK  
 PA Topo Target ApS DK (57956)  
 EXNAM Geist, Gary  
 EXNAM Crane, L. E  
 AG Cooper, Iver P.  
 PI US 6265385 B1 20010724  
 WO 9725044 19970717  
 AI US 1999-101499 19990308  
 WO 1997-DK13 19970110  
 19990308 PCT 371 date  
 19990308 PCT 102(e) date  
 XPD 10 Jan 2017  
 PRAI DK 1996-22 19960111  
 FI US 6265385 20010724  
 DT Utility; Reassigned



FS      CHEMICAL  
          GRANTED  
 ED      Entered STN: 26 Jul 2001  
          Last Updated on STN: 8 Jul 2002  
 MRN     011670      MFN: 0172  
          011670          0179  
 CLMN    54  
 GI      1 Drawing Sheet(s), 1 Figure(s).  
 AB      The present invention relates to a method for selectively killing tumor or metastatic cells within a defined compartment of the organism of a large mammal, in particular a human, said method comprising administering to a mammal an effective tumor-or metastasis-killing amount of a topoisomerase II poison except doxorubicin, and protecting non-tumorous tissue of the mammal against the toxic action of the topoisomerase II poison by administration of a bis-dioxypiperazine compound. In particular, the invention relates to a pharmaceutical kit for selectively killing tumor or metastatic cells within the central nervous system in a large mammal, in particular a human, said kit comprising: a) a dosage unit of a bis-dioxypiperazine and a pharmaceutically acceptable carrier, and b) a dosage unit of topoisomerase II poisons except doxorubicin and a pharmaceutically acceptable carrier.

CLMN    54  
 GI      1 Drawing Sheet(s), 1 Figure(s).

L3      ANSWER 10 OF 21   SCISEARCH   COPYRIGHT (c) 2008 The Thomson Corporation   on STN  
 AN      2007:1060925   SCISEARCH  
 GA      The Genuine Article (R) Number: 211YZ  
 TI      A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase II alpha in vivo  
 AU      Grauslund, Morten; Thougard, Annemette Vinding; Fuechtbauer, Annette; Hofland, Kenneth Francis; Hjorth, Peter Hansen; Jensen, Peter B.; Sehested, Maxwell; Fuechtbauer, Ernst-Martin; Jensen, Lars H. (Reprint)  
 CS      Rigshosp, Dept Pathol, Expt Pathol Unit, Bioctr, Bygning 2, 3 Sal, Ole Maaloes Vej 5, DK-2100 Copenhagen O, Denmark (Reprint); Univ Copenhagen Hosp, Dept Pathol, Expt Pathol Unit, DK-2100 Copenhagen, Denmark; Topo Target AS, Copenhagen, Denmark; Univ Aarhus, Dept Mol Biol, Aarhus, Denmark; Univ Copenhagen Hosp, Finsen Ctr, Lab Expt Med Oncol, DK-2100 Copenhagen, Denmark  
          lhj@topotarget.com  
 CYA     Denmark  
 SO      MOLECULAR PHARMACOLOGY, (OCT 2007) Vol. 72, No. 4, pp. 1003-1014.  
          ISSN: 0026-895X.  
 PB      AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA.  
 DT      Article; Journal  
 LA      English  
 REC     Reference Count: 40  
 ED      Entered STN: 18 Oct 2007  
          Last Updated on STN: 18 Oct 2007  
          \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*  
 AB      The bisdioxopiperazines such as (+)-(S)-4,4 '-propylenedi-2,6-piperazinedione (dexrazoxane; ICRF-187), 1,2-bis( 3,5-dioxopiperazinyl) ethane (ICRF-154), and 4,4 '-(1,2-dimethyl-1,2-ethanediy) bis-2,6-piperazinedione (ICRF-193) are agents that inhibit eukaryotic topoisomerase II, whereas their ring-opened hydrolysis products are strong iron chelator. The clinically approved analog ICRF-187 is a pharmacological modulator of topoisomerase II poisons such as etoposide in preclinical animal models.   ICRF- 187

is also used to protect against anthracycline-induced cardiomyopathy and has recently been approved as an antidote for alleviating tissue damage and necrosis after accidental anthracycline extravasation. This dual modality of bisdioxopiperazines, including ICRF-187, raises the question of whether their pharmacological in vivo effects are mediated through interaction with topoisomerase II or via their intracellular iron chelating activity. In an attempt to distinguish between these possibilities, we here present a transgenic mouse model aimed at identifying the contribution of topoisomerase II alpha to the effects of bisdioxopiperazines. A tyrosine 165 to serine mutation (Y165S) in topoisomerase II alpha, demonstrated previously to render the human ortholog of this enzyme highly resistant toward bisdioxopiperazines, was introduced at the TOP2A locus in mouse embryonic stem cells by targeted homologous recombination. These cells were used for the generation of transgenic TOP2A(Y165S/+) mice, which were demonstrated to be resistant toward the general toxicity of both ICRF-187 and ICRF-193. Hematological measurements indicate that this is most likely caused by a decreased ability of these agents to induce myelosuppression in TOP2A(Y165S/+) mice, highlighting the role of topoisomerase II alpha in this process. The biological and pharmacological implications of these findings are discussed, and areas for further investigations are proposed.

L3 ANSWER 11 OF 21 USPATFULL on STN  
AN 2007:224264 USPATFULL  
TI SUCCINIMIDE AND MALEIMIDE DERIVATIVES AND THEIR USE AS TOPOISOMERASE II CATALYTIC INHIBITORS  
IN Jensen, Peter Buhl, Farum, DENMARK  
Sokilde, Birgitte, Vaerloose, DENMARK  
Carstensen, Elisabeth Vang, Farum, DENMARK  
Langer, Seppo W., Gentofte, DENMARK  
Creighton, Andrew, London, UNITED KINGDOM  
Sehested, Maxwell, Copenhagen, DENMARK  
Jensen, Lars Hollund, Valby, DENMARK  
PA TOPOTARGET A/S (non-U.S. corporation)  
PI US 20070196360 A1 20070823  
AI US 2006-557631 A1 20061108 (11)  
RLI Continuation of Ser. No. US 2002-108979, filed on 29 Mar 2002, ABANDONED  
PRAI DK 2001-522 20010329  
US 2001-279459P 20010329 (60)  
DT Utility  
FS APPLICATION  
LREP FOLEY AND LARDNER LLP, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007, US  
CLMN Number of Claims: 3  
ECL Exemplary Claim: 1-47  
DRWN 11 Drawing Page(s)  
LN.CNT 1838  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Maleimide and succinimide derivatives were found to be effective topoisomerase II catalytic inhibitors. Due to this property, the maleimide and succinimide derivatives were investigated for their use as cytostatic agents and thus in the treatment of cancer. The compounds of the invention can be used in combination treatments with other cytostatic agents, such as topoisomerase II poisons. The maleimide and succinimide derivatives, due to their effective topoisomerase II catalytic inhibitory activity, are also useful as extravasation agents, such as upon administration of a topoisomerase II poison.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 21 USPATFULL on STN  
 AN 2007:211316 USPATFULL  
 TI Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation  
 IN Hofland, Kenneth, Copenhagen, DENMARK  
 Sehested, Maxwell, Copenhagen, DENMARK  
 Kristjansen, Paul, Copenhagen, DENMARK  
 Thougard, Annenette, Copenhagen, DENMARK  
 Jensen, Peter Buhl, Copenhagen, DENMARK  
 PI US 20070185124 A1 20070809  
 AI US 2005-591847 A1 20050302 (10)  
 WO 2005-IB670 20050302  
 20070109 PCT 371 date  
 PRAI GB 2004-4675 20040302  
 DT Utility  
 FS APPLICATION  
 LREP NIXON & VANDERHYE, PC, 901 NORTH GLEBE ROAD, 11TH FLOOR, ARLINGTON, VA, 22203, US  
 CLMN Number of Claims: 10  
 ECL Exemplary Claim: 1  
 DRWN 2 Drawing Page(s)  
 LN.CNT 681  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention relates to a method of treatment of a tumour cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane wherein said subject is further treated with radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 21 USPATFULL on STN  
 AN 2007:36275 USPATFULL  
 TI Screening method for identifying hsp90 modulators  
 IN Jenkins, John, Liverpool, UNITED KINGDOM  
 Greenhalf, William, Liverpool, UNITED KINGDOM  
 O'Connor, David Ian, Staffordshire, UNITED KINGDOM  
 PA University of Liverpool, Liverpool, UNITED KINGDOM, L69 3BX (non-U.S. corporation)  
 PI US 20070031815 A1 20070208  
 AI US 2004-554973 A1 20040428 (10)  
 WO 2004-GB1828 20040428  
 20051031 PCT 371 date  
 PRAI GB 2003-10017 20030501  
 DT Utility  
 FS APPLICATION  
 LREP DAVIS WRIGHT TREMAINE LLP, 865 FIGUEROA STREET, SUITE 2400, LOS ANGELES, CA, 90017-2566, US  
 CLMN Number of Claims: 20  
 ECL Exemplary Claim: 1  
 DRWN 6 Drawing Page(s)  
 LN.CNT 962  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB A screening method for identifying and/or analysing Hsp90 inhibitors and/or Hsp90 agonists comprises the steps of contacting a compound with at least two of yeast strains A-E wherein each yeast strain comprises expression vectors from which a pair of binding partners for a yeast two-hybrid assay are expressed. The binding partner pairs comprise: A: Hsp90-targeting protein; B: Hsp90-Hsp90; C: Hsp90-p23; D: Hsp90-E3 ligase; E: Hsp90-Client. Inhibition and/or promotion of dimerisation

between the binding partners is then measured.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 21 USPATFULL on STN  
AN 2006:282242 USPATFULL  
TI Alkylating agent combinations in the treatment of cancer  
IN Gerson, Stanton L., Huntington Valley, OH, UNITED STATES  
Liu, Lili, Northfield, OH, UNITED STATES  
PI US 20060241186 A1 20061026  
AI US 2003-505400 A1 20030219 (10)  
WO 2003-US5032 20030219  
20050622 PCT 371 date  
RLI Continuation of Ser. No. US 2002-79049, filed on 19 Feb 2002, GRANTED,  
Pat. No. US 6635677 Continuation-in-part of Ser. No. US 1999-373693,  
filed on 13 Aug 1999, GRANTED, Pat. No. US 6465448  
DT Utility  
FS APPLICATION  
LREP FISH & NEAVE IP GROUP, ROPES & GRAY LLP, ONE INTERNATIONAL PLACE,  
BOSTON, MA, 02110-2624, US  
CLMN Number of Claims: 43  
ECL Exemplary Claim: 1  
DRWN 24 Drawing Page(s)  
LN.CNT 2099

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This application provides compositions and methods useful in the  
treatment of certain cancers. In part, this application is based on the  
recognition that certain molecules that target abasic lesions or AP  
sites in DNA improve, augment, or potentiate the chemotherapeutic  
efficacy of certain anticancer agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 21 USPATFULL on STN  
AN 2003:45313 USPATFULL  
TI Succinimide and maleimide derivatives and their use as topoisomerase II  
catalytic inhibitors  
IN Jensen, Peter Buhl, Farum, DENMARK  
Sokilde, Birgitte, Vaerloose, DENMARK  
Carstensen, Elisabeth Vang, Farum, DENMARK  
Langer, Seppo W., Gentofte, DENMARK  
Creighton, Andrew, London, UNITED KINGDOM  
Sehested, Maxvell, Copenhagen, DENMARK  
Jensen, Lars Hollund, Valby, DENMARK  
PA Topo Target ApS, Copenhagen, DENMARK (non-U.S. corporation)  
PI US 20030032625 A1 20030213  
AI US 2002-108979 A1 20020329 (10)  
PRAI DK 2001-522 20010329  
US 2001-279459P 20010329 (60)  
DT Utility  
FS APPLICATION  
LREP BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300,  
WASHINGTON, DC, 20001-5303  
CLMN Number of Claims: 48  
ECL Exemplary Claim: 1  
DRWN 11 Drawing Page(s)  
LN.CNT 2174

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Maleimide and succinimide derivatives were found to be effective  
topoisomerase II catalytic inhibitors. Due to this property, the  
maleimide and succinimide derivatives were investigated for their use as

cytostatic agents and thus in the treatment of cancer. The compounds of the invention can be used in combination treatments with other cytostatic agents, such as topoisomerase II poisons. The maleimide and succinimide derivatives, due to their effective topoisomerase II catalytic inhibitory activity, are also useful as extravasation agents, such as upon administration of a topoisomerase II poison.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 21 USPATFULL on STN  
AN 2002:186136 USPATFULL  
TI Treatment of accidental extravasation of anthracyclines  
IN Langer, Seppo W., Gentofte, DENMARK  
Jensen, Peter B., Farum, DENMARK  
Sehested, Maxwell, Copenhagen, DENMARK  
PI US 20020099057 A1 20020725  
US 6727253 B2 20040427  
AI US 2001-893521 A1 20010629 (9)  
RLI Continuation-in-part of Ser. No. WO 2000-DK107, filed on 13 Mar 2000,  
UNKNOWN  
PRAI DK 1999-355 19990312  
DT Utility  
FS APPLICATION  
LREP BROWDY AND NEIMARK, P.L.L.C., 624 NINTH STREET, NW, SUITE 300,  
WASHINGTON, DC, 20001-5303  
CLMN Number of Claims: 51  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Page(s)  
LN.CNT 1375

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method and a medicament for pharmacological treatment of accidental extravasation of topoisomerase II poisons such as anthracyclines. In particular, the invention relates to the use of a topo II catalytic inhibitor such as the bisdioxopiperazine ICRF-187 for the manufacture of a medicament for the treatment of an accidental extravasation of a topoisomerase II poison and a method for treatment of such extravasation of a topoisomerase poison such as the anthracyclines daunorubicin, doxorubicin, epirubicin, or idarubicin. In addition, the invention relates to a kit for such treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 21 USPATFULL on STN  
AN 2001:116991 USPATFULL  
TI Topoisomerase II poison and  
bis-dioxopiperazine derivative combination therapy  
IN Jensen, Peter Buhl, Farum, Denmark  
Sehested, Maxwell, K.o slashed.benhavn .O slashed., Denmark  
PA Topo Target ApS, Copenhagen, Denmark (non-U.S. corporation)  
PI US 6265385 B1 20010724  
WO 9725044 19970717  
AI US 1999-101499 19990308 (9)  
WO 1997-DK13 19970110  
19990308 PCT 371 date  
19990308 PCT 102(e) date  
PRAI DK 1996-22 19960111  
DT Utility  
FS GRANTED

EXNAM Primary Examiner: Geist, Gary; Assistant Examiner: Crane, L. E.  
LREP Cooper, Iver P.  
CLMN Number of Claims: 54  
ECL Exemplary Claim: 1,12,43  
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
LN.CNT 1373

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for selectively killing tumor or metastatic cells within a defined compartment of the organism of a large mammal, in particular a human, said method comprising administering to a mammal an effective tumor--or metastasis-killing amount of a topoisomerase II poison except doxorubicin, and protecting non-tumorous tissue of the mammal against the toxic action of the topoisomerase II poison by administration of a bis-dioxypiperazine compound. In particular, the invention relates to a pharmaceutical kit for selectively killing tumor or metastatic cells within the central nervous system in a large mammal, in particular a human, said kit comprising: a) a dosage unit of a bis-dioxypiperazine and a pharmaceutically acceptable carrier, and b) a dosage unit of topoisomerase II poisons except doxorubicin and a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 18 OF 21 USPAT2 on STN  
AN 2002:186136 USPAT2  
TI Treatment of accidental extravasation of anthracyclines  
IN Langer, Seppo W., Gentofte, DENMARK  
Jensen, Peter B., Farum, DENMARK  
Sehested, Maxwell, Copenhagen, DENMARK  
PA Antianthra APS, Farum, DENMARK (non-U.S. corporation)  
PI US 6727253 B2 20040427  
AI US 2001-893521 20010629 (9)  
RLI Continuation-in-part of Ser. No. WO 2000-DK107, filed on 13 Mar 2000  
PRAI DK 1999-355 19990312  
DT Utility  
FS GRANTED

EXNAM Primary Examiner: Spivack, Phyllis G.  
LREP Cooper, Iver P.  
CLMN Number of Claims: 31  
ECL Exemplary Claim: 1  
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)  
LN.CNT 1327

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for pharmacological treatment of accidental extravasation of topoisomerase II poisons, such as anthracyclines. In particular, the invention relates to the use of a topo II catalytic inhibitor, such as the bisdioxopiperazine ICRF-187, for the treatment of an accidental extravasation of a topoisomerase II poison . A method for treatment of such extravasation of a topoisomerase poison such as the anthracyclines, daunorubicin, doxorubicin, epirubicin, or idarubicin is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 19 OF 21 WPINDEX COPYRIGHT 2008 THOMSON REUTERS on STN  
AN 1997-372598 [34] WPINDEX  
DNC C1997-120018 [34]  
TI Selective killing of tumour or metastatic cells - using

topoisomerase II poison except doxorubicin and  
bis-dioxypiperazine compound to protect non-tumourous tissue  
DC B03; B05  
IN JENSEN P; JENSEN P B; LENSEN P B; SEHESTED M  
PA (JENS-I) JENSEN P; (JENS-I) JENSEN P B; (SEHE-I) SEHESTED M; (TOPO-N) TOPO  
TARGET APS; (TOPO-N) TOPOTARGET APS

CYC 72

PIA WO 9725044 A1 19970717 (199734)\* EN 53[1]  
AU 9713677 A 19970801 (199748) EN  
EP 874630 A1 19981104 (199848) EN  
US 6265385 B1 20010724 (200146) EN  
EP 874630 B1 20030820 (200356) EN  
DE 69724228 E 20030925 (200371) DE  
ES 2205164 T3 20040501 (200431) ES

ADT WO 9725044 A1 WO 1997-DK13 19970110; AU 9713677 A AU 1997-13677 19970110;  
DE 69724228 E DE 1997-69724228 19970110; EP 874630 A1 EP 1997-900205  
19970110; EP 874630 B1 EP 1997-900205 19970110; DE 69724228 E EP  
1997-900205 19970110; ES 2205164 T3 EP 1997-900205 19970110; AU 9713677 A  
WO 1997-DK13 19970110; EP 874630 A1 WO 1997-DK13 19970110; US 6265385 B1  
WO 1997-DK13 19970110; EP 874630 B1 WO 1997-DK13 19970110; DE 69724228 E  
WO 1997-DK13 19970110; US 6265385 B1 US 1999-101499 19990308

FDT DE 69724228 E Based on EP 874630 A; ES 2205164 T3 Based on EP 874630 A; AU  
9713677 A Based on WO 9725044 A; EP 874630 A1 Based on WO 9725044 A; US  
6265385 B1 Based on WO 9725044 A; EP 874630 B1 Based on WO 9725044 A; DE  
69724228 E Based on WO 9725044 A

PRAI US 1996-603105 19960220  
DK 1996-22 19960111

AN 1997-372598 [34] WPINDEX

AB WO 1997025044 A1 UPAB: 20050703

Method for selectively killing tumour or metastatic cells within a  
compartment of the organism of a large mammal, in particular a human,  
comprises administering a topoisomerase II  
poison (T II P) except doxorubicin, and protecting non-tumourous  
tissue of the mammal against the toxic action of the T II P by  
administration of a bis-dioxypiperazine compound (BDC).  
Also claimed is a kit for selectively killing tumour or metastatic cells  
within the central nervous system (CNS) of a large mammal, particularly a  
human, comprising:

- (a) a dosage unit of a BDC and a carrier, and
- (b) a dosage unit of T II P except doxorubicin and a carrier.

USE - The method can be used for selectively killing tumour or  
metastatic cells, particularly in the CNS of humans (all claimed).

ADVANTAGE - Using the method the normal tissue is protected from the  
poison by the bis-dioxypiperazine whereby the malignant  
conditions can be treated with higher dosages of the T II P and side  
effects are reduced.

Member(0003)

ABEQ EP 874630 A1 UPAB 20050703

Method for selectively killing tumour or metastatic cells within a  
compartment of the organism of a large mammal, in particular a human,  
comprises administering a topoisomerase II  
poison (T II P) except doxorubicin, and protecting non-tumourous  
tissue of the mammal against the toxic action of the T II P by  
administration of a bis-dioxypiperazine compound (BDC).  
Also claimed is a kit for selectively killing tumour or metastatic cells  
within the central nervous system (CNS) of a large mammal, particularly a  
human, comprising:

- (a) a dosage unit of a BDC and a carrier, and
- (b) a dosage unit of T II P except doxorubicin and a carrier.

USE - The method can be used for selectively killing tumour or

metastatic cells, particularly in the CNS of humans (all claimed).

ADVANTAGE - Using the method the normal tissue is protected from the poison by the bis-dioxypiperazine whereby the malignant conditions can be treated with higher dosages of the T II P and side effects are reduced.

Member(0004)

ABEQ US 6265385 B1 UPAB 20050703

Method for selectively killing tumour or metastatic cells within a compartment of the organism of a large mammal, in particular a human, comprises administering a topoisomerase II poison (T II P) except doxorubicin, and protecting non-tumourous tissue of the mammal against the toxic action of the T II P by administration of a bis-dioxypiperazine compound (BDC). Also claimed is a kit for selectively killing tumour or metastatic cells within the central nervous system (CNS) of a large mammal, particularly a human, comprising:

- (a) a dosage unit of a BDC and a carrier, and
- (b) a dosage unit of T II P except doxorubicin and a carrier.

USE - The method can be used for selectively killing tumour or metastatic cells, particularly in the CNS of humans (all claimed).

ADVANTAGE - Using the method the normal tissue is protected from the poison by the bis-dioxypiperazine whereby the malignant conditions can be treated with higher dosages of the T II P and side effects are reduced.

L3 ANSWER 20 OF 21 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN

AN 2008097296 EMBASE

TI Mutagenicity of some topoisomerase II-interactive agents.

AU Attia, Sabry M. (correspondence)

CS Department of Pharmacology, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia. attiasm@yahoo.com

SO Saudi Pharmaceutical Journal, (Jan 2008) Vol. 16, No. 1, pp. 1-24.

Refs: 207

ISSN: 1319-0164 CODEN: SPJOEM

CY Saudi Arabia

DT Journal; General Review; (Review)

FS 016 Cancer

017 Public Health, Social Medicine and Epidemiology

022 Human Genetics

037 Drug Literature Index

038 Adverse Reactions Titles

LA English

SL English; Arabic

ED Entered STN: 4 Apr 2008

Last Updated on STN: 4 Apr 2008

AB Among the anticancer drugs currently used in the treatment of human malignancies, as well as several new series of drugs under development, are targeted at topoisomerase II enzymes. Besides of inducing cell death due to both 'mitotic catastrophe' and the induction of apoptosis, topoisomerase-II-targeted drugs can increase the frequency of cells bearing mutations. These cells can develop resistance to the therapeutic agents or may lead to the development of secondary tumours and abnormal reproductive outcomes. This review focuses on the mutagenic properties of the topoisomerase II poisons etoposide, doxorubicin and amsacrine, which are front-line therapies for a variety of malignancies, and genistein, which is prominent in soybean foods and is believed to be a chemopreventative agent that contributes to the low incidence of specific cancers among Asian populations. In addition, the topoisomerase II catalytic inhibitor merbarone that is in clinical trials



as an anticancer agent will be discussed. It clear from the present review that, the topoisomerase II-interactive anticancer agents appear to be mutagenic. Therefore, the clinical use of these mutagenic drugs must be weighed against the risks of secondary malignancies in cured patients and persistent genetic damage of their potential offspring.

L3 ANSWER 21 OF 21 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN  
AN 2007472968 EMBASE  
TI A mouse model for studying the interaction of bisdioxopiperazines with topoisomerase II $\alpha$  in vivo.  
AU Grauslund, Morten; Sehested, Maxwell; Jensen, Lars H., Dr. (correspondence)  
CS Experimental Pathology Unit, Department of Pathology, Copenhagen University Hospital, Copenhagen, Denmark. lhj@topotarget.com  
AU Grauslund, Morten; Thougard, Annemette Vinding; Hofland, Kenneth Francis; Jensen, Peter B.; Sehested, Maxwell; Jensen, Lars H., Dr. (correspondence)  
CS TopoTarget A/S, Copenhagen, Denmark. lhj@topotarget.com  
AU Fuchtbauer, Annette; Hjorth, Peter Hansen; Fuchtbauer, Ernst-Martin  
CS Department of Molecular Biology, University of Aarhus, Aarhus, Denmark.  
AU Jensen, Peter B.  
CS Laboratory for Experimental Medical Oncology, Finsen Center, Copenhagen University Hospital, Copenhagen, Denmark.  
AU Jensen, Lars H., Dr. (correspondence)  
CS Department of Pathology, Rigshospitalet Afs. 3731, Biocenter, Bygning 2, 3 sal., Ole Maales vej 5, DK-2100 Copenhagen O, Denmark. lhj@topotarget.com  
SO Molecular Pharmacology, (Oct 2007) Vol. 72, No. 4, pp. 1003-1014.  
Refs: 40  
ISSN: 0026-895X E-ISSN: 1521-0111 CODEN: MOPMA3  
CY United States  
DT Journal; Article  
FS 030 Clinical and Experimental Pharmacology  
037 Drug Literature Index  
052 Toxicology  
LA English  
SL English  
ED Entered STN: 11 Oct 2007  
Last Updated on STN: 11 Oct 2007  
AB The bisdioxopiperazines such as (+)-(S)-4,4'-propylenedi-2,6-piperazinedione (dexrazoxane; ICRF-187), 1,2-bis(3,5-dioxopiperazin-1-yl)ethane (ICRF-154), and 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione (ICRF-193) are agents that inhibit eukaryotic topoisomerase II, whereas their ring-opened hydrolysis products are strong iron chelator. The clinically approved analog ICRF-187 is a pharmacological modulator of topoisomerase II poisons such as etoposide in preclinical animal models. ICRF-187 is also used to protect against anthracycline-induced cardiomyopathy and has recently been approved as an antidote for alleviating tissue damage and necrosis after accidental anthracycline extravasation. This dual modality of bisdioxopiperazines, including ICRF-187, raises the question of whether their pharmacological in vivo effects are mediated through interaction with topoisomerase II or via their intracellular iron chelating activity. In an attempt to distinguish between these possibilities, we here present a transgenic mouse model aimed at identifying the contribution of topoisomerase II $\alpha$  to the effects of bisdioxopiperazines. A tyrosine 165 to serine mutation (Y165S) in topoisomerase II $\alpha$ , demonstrated previously to render the human ortholog of this enzyme highly resistant toward bisdioxopiperazines, was introduced at the TOP2A locus in mouse embryonic stem cells by targeted homologous recombination. These cells were used for the generation of transgenic TOP2A (Y165S/+) mice, which were demonstrated to be resistant

toward the general toxicity of both ICRF-187 and ICRF-193. Hematological measurements indicate that this is most likely caused by a decreased ability of these agents to induce myelosuppression in TOP2A(Y165S/+) mice, highlighting the role of topoisomerase II $\alpha$  in this process. The biological and pharmacological implications of these findings are discussed, and areas for further investigations are proposed. Copyright .COPYRGT. 2007 The American Society for Pharmacology and Experimental Therapeutics.

```
=> s piperazinedione(w)radiation
L4          1 PIPERAZINEDIONE(W) RADIATION
```

```
=> dis l4 bib abs
```

```
L4  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2008 ACS on STN
AN  1977:113324  CAPLUS
DN  86:113324
OREF 86:17827a,17830a
TI  An ENDOR study of the  $\delta$  proton hyperfine interaction in x-ray
    damaged 2,5-piperazinedione
AU  Helms, H. A., Jr.; Miyagawa, Ichiro
CS  Dep. Phys. Astron., Univ. Alabama, University, AL, USA
SO  Journal of Chemical Physics (1976), 65(9), 3493-4
    CODEN: JCPSA6; ISSN: 0021-9606
DT  Journal
LA  English
AB  ENDOR studies of x-ray irradiated crystals of 2,5-piperazinedione were
    conducted. The structure of the primary radical reported in the previous
    ESR studies was confirmed, but anal. of the  $\delta$  proton hfs tensors
    showed that neither of the previously proposed models for hfs of the
     $\delta$  proton is correct. The present results indicate that practically
    all of the spin d. must be in the vicinity of the  $\alpha$  C.
```

```
=> s piperazinedione
L5          5385 PIPERAZINEDIONE
```

```
=> s l5 and radiation
L6          786 L5 AND RADIATION
```

```
=> s l6 and (anti(a)tumor)
L7          455 L6 AND (ANTI(A) TUMOR)
```

```
=> s l7 and toxicity
L8          433 L7 AND TOXICITY
```

```
=> s l8 and bis
L9          394 L8 AND BIS
```

```
=> s (bis and ethanediyl)
L10         6550 (BIS AND ETHANEDIYL)
```

```
=> s l8 and (bis and ethanediyl)
L11         67 L8 AND (BIS AND ETHANEDIYL)
```

```
=> s l11 and ionizing
L12         59 L11 AND IONIZING
```

```
=> dis l12 1-59 bib abs
```

L12 ANSWER 1 OF 59 USPATFULL on STN

AN 2008:152188 USPATFULL

TI Conformationally Constrained Smac Mimetics And The Uses Thereof

IN Wang, Shaomeng, Saline, MI, UNITED STATES

Sun, Haiying, Ann Arbor, MI, UNITED STATES

Nikolovksa-Coleska, Zaneta, Ann Arbor, MI, UNITED STATES

Yang, Chao-Yie, Ann Arbor, MI, UNITED STATES

Xu, Liang, Ann Arbor, MI, UNITED STATES

Saito, Naoyuki G., East Amherst, NY, UNITED STATES

Chen, Jianyong, Ann Arbor, MI, UNITED STATES

PI US 20080132485 A1 20080605

AI US 2005-632079 A1 20050711 (11)

WO 2005-US24530 20050711

20080220 PCT 371 date

PRAI US 2004-586575P 20040709 (60)

DT Utility

FS APPLICATION

LREP MEDLEN & CARROLL, LLP, 101 HOWARD STREET, SUITE 350, SAN FRANCISCO, CA, 94105, US

CLMN Number of Claims: 48

ECL Exemplary Claim: 1

DRWN 35 Drawing Page(s)

LN.CNT 2751

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 59 USPATFULL on STN

AN 2008:103430 USPATFULL

TI Bivalent SMAC mimetics and the uses thereof

IN Wang, Shaomeng, Saline, MI, UNITED STATES

Sun, Haiying, Ann Arbor, MI, UNITED STATES

Qin, Dongguang, Ann Arbor, MI, UNITED STATES

Nikolovska-Coleska, Zaneta, Ann Arbor, MI, UNITED STATES

Lu, Jianfeng, Ann Arbor, MI, UNITED STATES

Qiu, Su, Ann Arbor, MI, UNITED STATES

Peng, Yuefeng, Ann Arbor, MI, UNITED STATES

PA Regents of the University of Michigan, Ann Arbor, MI, UNITED STATES (U.S. corporation)

PI US 20080089896 A1 20080417

AI US 2007-800220 A1 20070504 (11)

PRAI US 2007-923415P 20070413 (60)

US 2006-798018P 20060505 (60)

DT Utility

FS APPLICATION

LREP MEDLEN & CARROLL, LLP, 101 HOWARD STREET, SUITE 350, SAN FRANCISCO, CA, 94105, US

CLMN Number of Claims: 61

ECL Exemplary Claim: 1

DRWN 6 Drawing Page(s)

LN.CNT 3298

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to bivalent mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 59 USPATFULL on STN

AN 2006:328918 USPATFULL

TI Electrical devices and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20060282123 A1 20061214

AI US 2004-6910 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING

Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE

6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 112

ECL Exemplary Claim: 1-2264

DRWN 32 Drawing Page(s)

LN.CNT 14774

AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L12 ANSWER 4 OF 59 USPATFULL on STN

AN 2006:174046 USPATFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20060147492 A1 20060706

AI US 2006-343809 A1 20060131 (11)

RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-518785P 20031110 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE

6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 52  
ECL Exemplary Claim: 1  
DRWN 28 Drawing Page(s)  
LN.CNT 56233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 59 USPATFULL on STN

AN 2005:241661 USPATFULL

TI Electrical devices and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050209666 A1 20050922

AI US 2004-6885 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE

6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 112

ECL Exemplary Claim: 1-630

DRWN 32 Drawing Page(s)

LN.CNT 14772

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 59 USPATFULL on STN

AN 2005:241660 USPATFULL

TI Electrical devices and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 20050209665 A1 20050922  
 AI US 2004-998351 A1 20041126 (10)  
 RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004,  
 PENDING Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov  
 2004, PENDING  
 PRAI US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 112  
 ECL Exemplary Claim: 1-11691  
 DRWN 32 Drawing Page(s)  
 LN.CNT 14777  
 AB Electrical devices (e.g., cardiac rhythm management and neurostimulation  
 devices) for contact with tissue are used in combination with an  
 anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit  
 scarring that may otherwise occur when the devices are implanted within  
 an animal.

L12 ANSWER 7 OF 59 USPATFULL on STN  
 AN 2005:241659 USPATFULL  
 TI Electrical devices and anti-scarring agents  
 IN Hunter, William L., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 20050209664 A1 20050922  
 AI US 2004-998349 A1 20041126 (10)  
 RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
 2004, PENDING  
 PRAI US 2004-586471P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 112  
 ECL Exemplary Claim: 1-1377  
 DRWN 32 Drawing Page(s)  
 LN.CNT 14786  
 AB Electrical devices (e.g., cardiac rhythm management and neurostimulation

devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L12 ANSWER 8 OF 59 USPATFULL on STN

AN 2005:240095 USPATFULL

TI Polymer compositions and methods for their use

IN Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050208095 A1 20050922

AI US 2004-996354 A1 20041122 (10)

RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 101

ECL Exemplary Claim: 1

DRWN 32 Drawing Page(s)

LN.CNT 34089

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 59 USPATFULL on STN

AN 2005:234693 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050203635 A1 20050915

AI US 2004-6909 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING

Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 76  
ECL Exemplary Claim: 1-3038  
DRWN 32 Drawing Page(s)  
LN.CNT 12596  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and  
nasal implants) are used in combination with an anti-scarring agent in  
order to inhibit scarring that may otherwise occur when the implant is  
placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 10 OF 59 USPATFULL on STN  
AN 2005:226572 USPATFULL  
TI Polymer compositions and methods for their use  
IN Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A E., North Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050196421 A1 20050908  
AI US 2004-1417 A1 20041201 (11)  
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING  
PRAI US 2004-611077P 20040917 (60)  
US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 100  
ECL Exemplary Claim: 1-7300  
DRWN 32 Drawing Page(s)  
LN.CNT 34222  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric  
compositions can be used in various medical applications including the  
prevention of surgical adhesions, treatment of inflammatory arthritis,  
treatment of scars and keloids, the treatment of vascular disease, and  
the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 11 OF 59 USPATFULL on STN  
AN 2005:221910 USPATFULL



TI Electrical devices and anti-scarring agents  
 IN Hunter, William L., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 20050192647 A1 20050901  
 AI US 2004-6898 A1 20041207 (11)  
 RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
 2004, PENDING  
 PRAI US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 112  
 ECL Exemplary Claim: 1-1992  
 DRWN 32 Drawing Page(s)  
 LN.CNT 14794  
 AB Electrical devices (e.g., cardiac rhythm management and neurostimulation  
 devices) for contact with tissue are used in combination with an  
 anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit  
 scarring that may otherwise occur when the devices are implanted within  
 an animal.

L12 ANSWER 12 OF 59 USPATFULL on STN  
 AN 2005:220596 USPATFULL  
 TI Medical implants and anti-scarring agents  
 IN Hunter, William L., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 Signore, Pierre E., Vancouver, CANADA  
 Liggins, Richard T., Coquitlam, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 20050191331 A1 20050901  
 AI US 2004-1419 A1 20041130 (11)  
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING  
 PRAI US 2003-518785P 20031110 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-526541P 20031203 (60)  
 US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 178  
 ECL Exemplary Claim: 1-2104  
 DRWN 28 Drawing Page(s)  
 LN.CNT 56419

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 13 OF 59 USPATFULL on STN

AN 2005:215962 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)

PI US 20050187639 A1 20050825

AI US 2004-6892 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 101

ECL Exemplary Claim: 1-3470

DRWN 32 Drawing Page(s)

LN.CNT 12657

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 14 OF 59 USPATFULL on STN

AN 2005:215923 USPATFULL

TI Electrical devices and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)

PI US 20050187600 A1 20050825

AI US 2004-998350 A1 20041126 (10)

RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 112

ECL Exemplary Claim: 1-3352

DRWN 32 Drawing Page(s)

LN.CNT 14781

AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

L12 ANSWER 15 OF 59 USPATFULL on STN

AN 2005:215464 USPATFULL

TI Polymer compositions and methods for their use

IN Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050187140 A1 20050825

AI US 2004-408 A1 20041129 (11)

RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING

PRAI US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2004-611077P 20040917 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 103

ECL Exemplary Claim: 1-5846

DRWN 32 Drawing Page(s)

LN.CNT 34103

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 16 OF 59 USPATFULL on STN

AN 2005:214574 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050186246 A1 20050825

AI US 2004-6883 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING

Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 101

ECL Exemplary Claim: 1-2606

DRWN 32 Drawing Page(s)

LN.CNT 12658

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 17 OF 59 USPATFULL on STN

AN 2005:214573 USPATFULL

TI Implantable sensors and implantable pumps and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050186245 A1 20050825

AI US 2004-6880 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING

Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 112  
ECL Exemplary Claim: 1-2785  
DRWN 32 Drawing Page(s)  
LN.CNT 15059  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 18 OF 59 USPATFULL on STN  
AN 2005:214572 USPATFULL  
TI Polymer compositions and methods for their use  
IN Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050186244 A1 20050825  
AI US 2004-1790 A1 20041202 (11)  
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING  
PRAI US 2004-611077P 20040917 (60)  
US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 103  
ECL Exemplary Claim: 1-8540  
DRWN 32 Drawing Page(s)  
LN.CNT 34060  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric  
compositions can be used in various medical applications including the  
prevention of surgical adhesions, treatment of inflammatory arthritis,  
treatment of scars and keloids, the treatment of vascular disease, and  
the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 19 OF 59 USPATFULL on STN  
AN 2005:214567 USPATFULL

TI Implantable sensors and implantable pumps and anti-scarring agents  
 IN Hunter, William L., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 20050186239 A1 20050825  
 AI US 2004-6897 A1 20041207 (11)  
 RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
 2004, PENDING  
 PRAI US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 112  
 ECL Exemplary Claim: 1-3058  
 DRWN 32 Drawing Page(s)  
 LN.CNT 15050

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pumps and sensors for contact with tissue are used in combination with  
 an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
 inhibit scarring that may otherwise occur when the pumps and sensors are  
 implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 20 OF 59 USPATFULL on STN  
 AN 2005:212068 USPATFULL  
 TI Polymer compositions and methods for their use  
 IN Hunter, William L., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 Liggins, Richard T., Coquitlam, CANADA  
 Takacs-Cox, Aniko, North Vancouver, CANADA  
 Avelar, Rui, Vancouver, CANADA  
 Loss, Troy A.E., North Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 20050183731 A1 20050825  
 AI US 2004-6908 A1 20041207 (11)  
 RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING  
 PRAI US 2004-611077P 20040917 (60)  
 US 2004-586861P 20040709 (60)  
 US 2004-566569P 20040428 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 52  
ECL Exemplary Claim: 1-8061  
DRWN 32 Drawing Page(s)  
LN.CNT 34032  
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L12 ANSWER 21 OF 59 USPATFULL on STN

AN 2005:212065 USPATFULL  
TI Medical implants and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Signore, Pierre E., Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S. corporation)  
PI US 20050183728 A1 20050825  
AI US 2004-7836 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING  
PRAI US 2003-518785P 20031110 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
US 2003-525226P 20031124 (60)  
US 2003-526541P 20031203 (60)  
US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 178

ECL Exemplary Claim: 1-3411

DRWN 28 Drawing Page(s)

LN.CNT 56413

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

L12 ANSWER 22 OF 59 USPATFULL on STN

AN 2005:210011 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050182496 A1 20050818  
AI US 2004-6906 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 76  
ECL Exemplary Claim: 1-3902  
DRWN 32 Drawing Page(s)  
LN.CNT 12588  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and  
nasal implants) are used in combination with an anti-scarring agent in  
order to inhibit scarring that may otherwise occur when the implant is  
placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 23 OF 59 USPATFULL on STN  
AN 2005:209984 USPATFULL  
TI Electrical devices and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S.  
corporation)  
PI US 20050182469 A1 20050818  
AI US 2004-7837 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 120  
ECL Exemplary Claim: 1-2803  
DRWN 32 Drawing Page(s)  
LN.CNT 14838  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation



devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 24 OF 59 USPATFULL on STN  
AN 2005:209983 USPATFULL  
TI Electrical devices and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050182468 A1 20050818  
AI US 2004-6891 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 112  
ECL Exemplary Claim: 1-1720  
DRWN 32 Drawing Page(s)  
LN.CNT 14768

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 25 OF 59 USPATFULL on STN  
AN 2005:209982 USPATFULL  
TI Electrical devices and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050182467 A1 20050818  
AI US 2004-6884 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 112  
ECL Exemplary Claim: 1-1168  
DRWN 32 Drawing Page(s)  
LN.CNT 14785  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Electrical devices (e.g., cardiac rhythm management and neurostimulation  
devices) for contact with tissue are used in combination with an  
anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit  
scarring that may otherwise occur when the devices are implanted within  
an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 26 OF 59 USPATFULL on STN  
AN 2005:209978 USPATFULL  
TI Polymer compositions and methods for their use  
IN Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S.  
corporation)  
PI US 20050182463 A1 20050818  
AI US 2004-1788 A1 20041202 (11)  
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING  
PRAI US 2004-611077P 20040917 (60)  
US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 125  
ECL Exemplary Claim: 1-8059  
DRWN 32 Drawing Page(s)  
LN.CNT 34070  
AB Compositions comprising anti-fibrotic agent(s) and/or polymeric  
compositions can be used in various medical applications including the  
prevention of surgical adhesions, treatment of inflammatory arthritis,  
treatment of scars and keloids, the treatment of vascular disease, and  
the prevention of cartilage loss.

L12 ANSWER 27 OF 59 USPATFULL on STN  
AN 2005:209965 USPATFULL

TI Electrical devices and anti-scarring agents  
 IN Hunter, William L., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 20050182450 A1 20050818  
 AI US 2004-6890 A1 20041207 (11)  
 RLI Continuation of Ser. No. US 2004-996355, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
 2004, PENDING  
 PRAI US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 112  
 ECL Exemplary Claim: 1-349  
 DRWN 32 Drawing Page(s)  
 LN.CNT 14792  
 AB Electrical devices (e.g., cardiac rhythm management and neurostimulation  
 devices) for contact with tissue are used in combination with an  
 anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit  
 scarring that may otherwise occur when the devices are implanted within  
 an animal.

L12 ANSWER 28 OF 59 USPATFULL on STN  
 AN 2005:209494 USPATFULL  
 TI Medical implants and anti-scarring agents  
 IN Hunter, William L., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 Signore, Pierre E., Vancouver, CANADA  
 Liggins, Richard T., Coquitlam, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 20050181977 A1 20050818  
 AI US 2004-986231 A1 20041110 (10)  
 PRAI US 2003-518785P 20031110 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-526541P 20031203 (60)  
 US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 182  
 ECL Exemplary Claim: 1  
 DRWN 28 Drawing Page(s)  
 LN.CNT 56396  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB       Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12   ANSWER 29 OF 59   USPATFULL on STN

AN       2005:208533   USPATFULL

TI       Medical implants and anti-scarring agents

IN       Hunter, William L., Vancouver, CANADA

         Gravett, David M., Vancouver, CANADA

         Toleikis, Philip M., Vancouver, CANADA

         Maiti, Arpita, Vancouver, CANADA

         Signore, Pierre E., Vancouver, CANADA

         Liggins, Richard T., Coquitlam, CANADA

PA       Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI       US 20050181011       A1   20050818

AI       US 2004-1792       A1   20041202 (11)

RLI      Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI     US 2003-518785P       20031110 (60)

         US 2003-523908P       20031120 (60)

         US 2003-524023P       20031120 (60)

         US 2003-525226P       20031124 (60)

         US 2003-526541P       20031203 (60)

         US 2004-586861P       20040709 (60)

         US 2004-578471P       20040609 (60)

DT       Utility

FS       APPLICATION

LREP     SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
         6300, SEATTLE, WA, 98104-7092, US

CLMN     Number of Claims: 177

ECL      Exemplary Claim: 1-4994

DRWN     28 Drawing Page(s)

LN.CNT 56421

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB       Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 30 OF 59 USPATFULL on STN  
AN 2005:208532 USPATFULL  
TI Implantable sensors and implantable pumps and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050181010 A1 20050818  
AI US 2004-1789 A1 20041201 (11)  
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 109  
ECL Exemplary Claim: 1-296  
DRWN 32 Drawing Page(s)  
LN.CNT 15014  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 31 OF 59 USPATFULL on STN  
AN 2005:208531 USPATFULL  
TI Implantable sensors and implantable pumps and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050181009 A1 20050818  
AI US 2004-1787 A1 20041201 (11)  
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 110

ECL Exemplary Claim: 1-570

DRWN 32 Drawing Page(s)

LN.CNT 15035

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 32 OF 59 USPATFULL on STN

AN 2005:208530 USPATFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Signore, Pierre E., Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050181008 A1 20050818

AI US 2004-1786 A1 20041202 (11)

RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2003-518785P 20031110 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

US 2003-525226P 20031124 (60)

US 2003-526541P 20031203 (60)

US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 178

ECL Exemplary Claim: 1-4736

DRWN 28 Drawing Page(s)

LN.CNT 56377

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 33 OF 59 USPATFULL on STN

AN 2005:208529 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA  
    Maiti, Arpita, Vancouver, CANADA  
PA    Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI    US 20050181007          A1  20050818  
AI    US 2004-1415          A1  20041130 (11)  
RLI   Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
      Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
      PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
      2004, PENDING  
PRAI  US 2004-586861P         20040709 (60)  
      US 2004-578471P         20040609 (60)  
      US 2003-526541P         20031203 (60)  
      US 2003-525226P         20031124 (60)  
      US 2003-523908P         20031120 (60)  
      US 2003-524023P         20031120 (60)  
DT    Utility  
FS    APPLICATION  
LREP  SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
      6300, SEATTLE, WA, 98104-7092, US  
CLMN  Number of Claims: 126  
ECL   Exemplary Claim: 1-444  
DRWN  32 Drawing Page(s)  
LN.CNT 12675  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB    Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and  
      nasal implants) are used in combination with an anti-scarring agent in  
      order to inhibit scarring that may otherwise occur when the implant is  
      placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12  ANSWER 34 OF 59  USPATFULL on STN  
AN    2005:208527  USPATFULL  
TI    Implantable sensors and implantable pumps and anti-scarring agents  
IN    Hunter, William L., Vancouver, CANADA  
      Gravett, David M., Vancouver, CANADA  
      Toleikis, Philip M., Vancouver, CANADA  
      Maiti, Arpita, Vancouver, CANADA  
PA    Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S.  
      corporation)  
PI    US 20050181005         A1  20050818  
AI    US 2004-6901          A1  20041207 (11)  
RLI   Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
      Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
      PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
      2004, PENDING  
PRAI  US 2004-586861P         20040709 (60)  
      US 2004-578471P         20040609 (60)  
      US 2003-526541P         20031203 (60)  
      US 2003-525226P         20031124 (60)  
      US 2003-523908P         20031120 (60)  
      US 2003-524023P         20031120 (60)  
DT    Utility  
FS    APPLICATION  
LREP  SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
      6300, SEATTLE, WA, 98104-7092, US  
CLMN  Number of Claims: 112  
ECL   Exemplary Claim: 1-2510  
DRWN  32 Drawing Page(s)  
LN.CNT 15035  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 35 OF 59 USPATFULL on STN

AN 2005:205930 USPATFULL

TI Polymer compositions and methods for their use

IN Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050178396 A1 20050818

AI US 2004-6905 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2004-611077P 20040917 (60)

US 2004-586861P 20040709 (60)

US 2004-566569P 20040428 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 50

ECL Exemplary Claim: 1-8063

DRWN 32 Drawing Page(s)

LN.CNT 33965

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

L12 ANSWER 36 OF 59 USPATFULL on STN

AN 2005:205929 USPATFULL

TI Polymer compositions and methods for their use

IN Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

Liggins, Richard T., Coquitlam, CANADA

Takacs-Cox, Aniko, North Vancouver, CANADA

Avelar, Rui, Vancouver, CANADA

Loss, Troy A. E., North Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050178395 A1 20050818

AI US 2004-6900 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,



PENDING

PRAI US 2004-611077P 20040917 (60)  
US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)

DT Utility  
FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 58  
ECL Exemplary Claim: 1-7302  
DRWN 32 Drawing Page(s)  
LN.CNT 34043

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric  
compositions can be used in various medical applications including the  
prevention of surgical adhesions, treatment of inflammatory arthritis,  
treatment of scars and keloids, the treatment of vascular disease, and  
the prevention of cartilage loss.

L12 ANSWER 37 OF 59 USPATFULL on STN

AN 2005:203799 USPATFULL

TI Medical implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Signore, Pierre E., Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA

PA Angiotech International AG, Zug, SWITZERLAND, CH (non-U.S. corporation)

PI US 20050177225 A1 20050811

AI US 2004-6895 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
US 2003-518785P 20031110 (60)

DT Utility  
FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 173  
ECL Exemplary Claim: 1-11788  
DRWN 28 Drawing Page(s)  
LN.CNT 56371

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to  
inhibit scarring that may otherwise occur when the implant is placed  
within an animal. The agent may be any suitable anti-scarring agent,  
e.g., a cell cycle inhibitor, and may be used in conjunction with a  
second pharmaceutical agent, e.g., an antibiotic. Suitable implants  
include intravascular implants, a vascular graft or wrap implant, an  
implant for hemodialysis access, an implant that provides an anastomotic  
connection, ventricular assist implant, a prosthetic heart valve  
implant, an inferior vena cava filter implant, a peritoneal dialysis  
catheter implant, a central nervous system shunt, an intraocular lens,

an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 38 OF 59 USPATFULL on STN  
AN 2005:202285 USPATFULL  
TI Polymer compositions and methods for their use  
IN Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A.E., North Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050175703 A1 20050811  
AI US 2004-6888 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING  
PRAI US 2004-611077P 20040917 (60)  
US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 55  
ECL Exemplary Claim: 1-7576  
DRWN 32 Drawing Page(s)  
LN.CNT 33992

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 39 OF 59 USPATFULL on STN  
AN 2005:202247 USPATFULL  
TI Polymer compositions and methods for their use  
IN Hunter, William L., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
Takacs-Cox, Aniko, North Vancouver, CANADA  
Avelar, Rui, Vancouver, CANADA  
Loss, Troy A. E., North Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050175665 A1 20050811  
AI US 2004-6896 A1 20041207 (11)  
RLI Continuation of Ser. No. US 2004-996354, filed on 22 Nov 2004, PENDING

Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING

PRAI US 2004-611077P 20040917 (60)  
US 2004-586861P 20040709 (60)  
US 2004-566569P 20040428 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 51

ECL Exemplary Claim: 1-7822

DRWN 32 Drawing Page(s)

LN.CNT 33978

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising anti-fibrotic agent(s) and/or polymeric  
compositions can be used in various medical applications including the  
prevention of surgical adhesions, treatment of inflammatory arthritis,  
treatment of scars and keloids, the treatment of vascular disease, and  
the prevention of cartilage loss.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 40 OF 59 USPATFULL on STN

AN 2005:202246 USPATFULL

TI Implantable sensors and implantable pumps and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050175664 A1 20050811

AI US 2004-4672 A1 20041202 (11)

RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 109

ECL Exemplary Claim: 1-851

DRWN 32 Drawing Page(s)

LN.CNT 15038

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 41 OF 59 USPATFULL on STN  
AN 2005:202245 USPATFULL  
TI Medical implants and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Signore, Pierre E., Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050175663 A1 20050811  
AI US 2004-1791 A1 20041202 (11)  
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING  
PRAI US 2003-518785P 20031110 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
US 2003-525226P 20031124 (60)  
US 2003-526541P 20031203 (60)  
US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 180  
ECL Exemplary Claim: 1-3944  
DRWN 28 Drawing Page(s)  
LN.CNT 56451

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 42 OF 59 USPATFULL on STN  
AN 2005:195820 USPATFULL  
TI Implantable sensors and implantable pumps and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050169961 A1 20050804  
AI US 2004-4675 A1 20041202 (11)  
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 118  
ECL Exemplary Claim: 1-1941  
DRWN 32 Drawing Page(s)  
LN.CNT 15063  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 43 OF 59 USPATFULL on STN  
AN 2005:195819 USPATFULL  
TI Implantable sensors and implantable pumps and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND, 6304 (non-U.S.  
corporation)  
PI US 20050169960 A1 20050804  
AI US 2004-4671 A1 20041202 (11)  
RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 110  
ECL Exemplary Claim: 1-3328  
DRWN 32 Drawing Page(s)  
LN.CNT 15057  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Pumps and sensors for contact with tissue are used in combination with  
an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
inhibit scarring that may otherwise occur when the pumps and sensors are  
implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 44 OF 59 USPATFULL on STN  
AN 2005:190568 USPATFULL  
TI Medical implants and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 Signore, Pierre E., Vancouver, CANADA  
 Liggins, Richard T., Coquitlam, CANADA  
 PA Angiotech International AG, Zug, SWEDEN (non-U.S. corporation)  
 PI US 20050165488 A1 20050728  
 AI US 2004-6912 A1 20041207 (11)  
 RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING  
 PRAI US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 US 2003-518785P 20031110 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 176  
 ECL Exemplary Claim: 1-3153  
 DRWN 28 Drawing Page(s)  
 LN.CNT 56407  
 AB Implants are used in combination with an anti-scarring agent in order to  
 inhibit scarring that may otherwise occur when the implant is placed  
 within an animal. The agent may be any suitable anti-scarring agent,  
 e.g., a cell cycle inhibitor, and may be used in conjunction with a  
 second pharmaceutical agent, e.g., an antibiotic. Suitable implants  
 include intravascular implants, a vascular graft or wrap implant, an  
 implant for hemodialysis access, an implant that provides an anastomotic  
 connection, ventricular assist implant, a prosthetic heart valve  
 implant, an inferior vena cava filter implant, a peritoneal dialysis  
 catheter implant, a central nervous system shunt, an intraocular lens,  
 an implant for glaucoma drainage, a penile implant, an endotracheal  
 tube, a tracheostomy tube, a gastrointestinal device, and a spinal  
 implant.

L12 ANSWER 45 OF 59 USPATFULL on STN  
 AN 2005:182973 USPATFULL  
 TI Implantable sensors and implantable pumps and anti-scarring agents  
 IN Hunter, William L., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 20050158356 A1 20050721  
 AI US 2004-996352 A1 20041122 (10)  
 RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
 2004, PENDING  
 PRAI US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE

6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 117

ECL Exemplary Claim: 1

DRWN 32 Drawing Page(s)

LN.CNT 15058

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 46 OF 59 USPATFULL on STN

AN 2005:178293 USPATFULL

TI Implantable sensors and implantable pumps and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050154374 A1 20050714

AI US 2004-6882 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE

6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 112

ECL Exemplary Claim: 1-2240

DRWN 32 Drawing Page(s)

LN.CNT 15052

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 47 OF 59 USPATFULL on STN

AN 2005:176868 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050152948 A1 20050714

AI US 2004-7838 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,

PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 96

ECL Exemplary Claim: 1-2174

DRWN 32 Drawing Page(s)

LN.CNT 12627

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 48 OF 59 USPATFULL on STN

AN 2005:176867 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050152947 A1 20050714

AI US 2004-6903 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov 2004, PENDING

PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE 6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 96

ECL Exemplary Claim: 1-1742

DRWN 32 Drawing Page(s)

LN.CNT 12637

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 49 OF 59 USPATFULL on STN



AN 2005:176866 USPATFULL  
 TI Implantable sensors and implantable pumps and anti-scarring agents  
 IN Hunter, William L., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 20050152946 A1 20050714  
 AI US 2004-6894 A1 20041207 (11)  
 RLI Continuation of Ser. No. US 2004-996352, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
 2004, PENDING  
 PRAI US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 112  
 ECL Exemplary Claim: 1-1126  
 DRWN 32 Drawing Page(s)  
 LN.CNT 15056  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Pumps and sensors for contact with tissue are used in combination with  
 an anti-scarring agent (e.g., a cell cycle inhibitor) in order to  
 inhibit scarring that may otherwise occur when the pumps and sensors are  
 implanted within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 50 OF 59 USPATFULL on STN  
 AN 2005:176865 USPATFULL  
 TI Soft tissue implants and anti-scarring agents  
 IN Hunter, William L., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 Toleikis, Philip M., Vancouver, CANADA  
 Maiti, Arpita, Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 20050152945 A1 20050714  
 AI US 2004-6887 A1 20041207 (11)  
 RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
 Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
 PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
 2004, PENDING  
 PRAI US 2004-586861P 20040709 (60)  
 US 2004-578471P 20040609 (60)  
 US 2003-526541P 20031203 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-524023P 20031120 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
 6300, SEATTLE, WA, 98104-7092, US  
 CLMN Number of Claims: 96  
 ECL Exemplary Claim: 1-1310

DRWN 32 Drawing Page(s)

LN.CNT 12592

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 51 OF 59 USPATFULL on STN

AN 2005:176864 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050152944 A1 20050714

AI US 2004-6881 A1 20041207 (11)

RLI Continuation of Ser. No. US 2004-996353, filed on 22 Nov 2004, PENDING  
Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)

US 2003-525226P 20031124 (60)

US 2003-523908P 20031120 (60)

US 2003-524023P 20031120 (60)

DT Utility

FS APPLICATION

LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US

CLMN Number of Claims: 96

ECL Exemplary Claim: 1-878

DRWN 32 Drawing Page(s)

LN.CNT 12628

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 52 OF 59 USPATFULL on STN

AN 2005:176861 USPATFULL

TI Soft tissue implants and anti-scarring agents

IN Hunter, William L., Vancouver, CANADA

Gravett, David M., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA

Maiti, Arpita, Vancouver, CANADA

PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)

PI US 20050152941 A1 20050714

AI US 2004-996353 A1 20041122 (10)

RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING

PRAI US 2004-586861P 20040709 (60)

US 2004-578471P 20040609 (60)

US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 132  
ECL Exemplary Claim: 1  
DRWN 32 Drawing Page(s)  
LN.CNT 12685  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and  
nasal implants) are used in combination with an anti-scarring agent in  
order to inhibit scarring that may otherwise occur when the implant is  
placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 53 OF 59 USPATFULL on STN  
AN 2005:172409 USPATFULL  
TI Medical implants and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Signore, Pierre E., Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050149158 A1 20050707  
AI US 2004-409 A1 20041129 (11)  
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING  
PRAI US 2003-518785P 20031110 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
US 2003-525226P 20031124 (60)  
US 2003-526541P 20031203 (60)  
US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 178  
ECL Exemplary Claim: 1-274  
DRWN 28 Drawing Page(s)  
LN.CNT 56404  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Implants are used in combination with an anti-scarring agent in order to  
inhibit scarring that may otherwise occur when the implant is placed  
within an animal. The agent may be any suitable anti-scarring agent,  
e.g., a cell cycle inhibitor, and may be used in conjunction with a  
second pharmaceutical agent, e.g., an antibiotic. Suitable implants  
include intravascular implants, a vascular graft or wrap implant, an  
implant for hemodialysis access, an implant that provides an anastomotic  
connection, ventricular assist implant, a prosthetic heart valve  
implant, an inferior vena cava filter implant, a peritoneal dialysis  
catheter implant, a central nervous system shunt, an intraocular lens,  
an implant for glaucoma drainage, a penile implant, an endotracheal  
tube, a tracheostomy tube, a gastrointestinal device, and a spinal

implant.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 54 OF 59 USPATFULL on STN  
AN 2005:172408 USPATFULL  
TI Electrical devices and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050149157 A1 20050707  
AI US 2004-996355 A1 20041122 (10)  
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 111  
ECL Exemplary Claim: 1  
DRWN 32 Drawing Page(s)  
LN.CNT 14769

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Electrical devices (e.g., cardiac rhythm management and neurostimulation  
devices) for contact with tissue are used in combination with an  
anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit  
scarring that may otherwise occur when the devices are implanted within  
an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 55 OF 59 USPATFULL on STN  
AN 2005:172331 USPATFULL  
TI Medical implants and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
Signore, Pierre E., Vancouver, CANADA  
Liggins, Richard T., Coquitlam, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050149080 A1 20050707  
AI US 2004-1418 A1 20041130 (11)  
RLI Continuation of Ser. No. US 2004-986231, filed on 10 Nov 2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-525226P 20031124 (60)  
US 2003-523908P 20031120 (60)  
US 2003-524023P 20031120 (60)  
US 2003-518785P 20031110 (60)  
DT Utility

FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 178  
ECL Exemplary Claim: 1-806  
DRWN 28 Drawing Page(s)  
LN.CNT 56418  
AB Implants are used in combination with an anti-scarring agent in order to  
inhibit scarring that may otherwise occur when the implant is placed  
within an animal. The agent may be any suitable anti-scarring agent,  
e.g., a cell cycle inhibitor, and may be used in conjunction with a  
second pharmaceutical agent, e.g., an antibiotic. Suitable implants  
include intravascular implants, a vascular graft or wrap implant, an  
implant for hemodialysis access, an implant that provides an anastomotic  
connection, ventricular assist implant, a prosthetic heart valve  
implant, an inferior vena cava filter implant, a peritoneal dialysis  
catheter implant, a central nervous system shunt, an intraocular lens,  
an implant for glaucoma drainage, a penile implant, an endotracheal  
tube, a tracheostomy tube, a gastrointestinal device, and a spinal  
implant.

L12 ANSWER 56 OF 59 USPATFULL on STN  
AN 2005:164738 USPATFULL  
TI Soft tissue implants and anti-scarring agents  
IN Hunter, William L., Vancouver, CANADA  
Gravett, David M., Vancouver, CANADA  
Toleikis, Philip M., Vancouver, CANADA  
Maiti, Arpita, Vancouver, CANADA  
PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
PI US 20050142162 A1 20050630  
AI US 2004-1416 A1 20041201 (11)  
RLI Continuation-in-part of Ser. No. US 2004-986231, filed on 10 Nov 2004,  
PENDING Continuation-in-part of Ser. No. US 2004-986230, filed on 10 Nov  
2004, PENDING  
PRAI US 2004-586861P 20040709 (60)  
US 2004-578471P 20040609 (60)  
US 2003-526541P 20031203 (60)  
US 2003-524023P 20031120 (60)  
US 2003-523908P 20031120 (60)  
US 2003-525226P 20031124 (60)  
DT Utility  
FS APPLICATION  
LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVENYUE, SUITE  
6300, SEATTLE, WA, 98104-7092, US  
CLMN Number of Claims: 117  
ECL Exemplary Claim: 1-4334  
DRWN 32 Drawing Page(s)  
LN.CNT 12679  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and  
nasal implants) are used in combination with an anti-scarring agent in  
order to inhibit scarring that may otherwise occur when the implant is  
placed within an animal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 57 OF 59 USPATFULL on STN  
AN 2004:328492 USPATFULL  
TI Anastomotic connector devices  
IN Hunter, William L., Vancouver, CANADA

Toleikis, Philip M., Vancouver, CANADA  
 Gravett, David M., Vancouver, CANADA  
 PA Angiotech International AG, Zug, SWITZERLAND (non-U.S. corporation)  
 PI US 20040260318 A1 20041223  
 AI US 2004-853023 A1 20040524 (10)  
 PRAI US 2003-473185P 20030523 (60)  
 US 2003-523908P 20031120 (60)  
 US 2003-525226P 20031124 (60)  
 US 2003-526541P 20031203 (60)  
 DT Utility  
 FS APPLICATION  
 LREP SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300,  
 SEATTLE, WA, 98104-7092  
 CLMN Number of Claims: 117  
 ECL Exemplary Claim: 1  
 DRWN 19 Drawing Page(s)  
 LN.CNT 6906  
 AB Anastomotic connector devices are provided which release a therapeutic  
 agent. The therapeutic agent may be an anti-scarring agent that inhibits  
 stenosis caused by the presence of the anastomotic connector device.

L12 ANSWER 58 OF 59 USPATFULL on STN  
 AN 2004:274400 USPATFULL  
 TI Small molecule antagonists of BCL-2 family proteins  
 IN Wang, Shaomeng, Saline, MI, UNITED STATES  
 Yang, Dajun, Rockville, MD, UNITED STATES  
 PA The Regents of the University of Michigan, Ann Arbor, MI (U.S.  
 corporation)  
 Georgetown University, Washington, DC (U.S. corporation)  
 PI US 20040214902 A1 20041028  
 AI US 2003-729156 A1 20031205 (10)  
 RLI Continuation-in-part of Ser. No. US 2002-158769, filed on 30 May 2002,  
 ABANDONED Continuation-in-part of Ser. No. WO 2002-US17206, filed on 30  
 May 2002, PENDING  
 PRAI US 2001-293983P 20010530 (60)  
 DT Utility  
 FS APPLICATION  
 LREP David A. Casimir, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street,  
 San Francisco, CA, 94105  
 CLMN Number of Claims: 51  
 ECL Exemplary Claim: 1  
 DRWN 55 Drawing Page(s)  
 LN.CNT 8211  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The present invention relates to naturally occurring and chemically  
 synthesized small molecule antagonists of Bcl-2 family proteins. In  
 particular, the present invention provides gossypol compounds (e.g.,  
 isomers, enantiomers, racemic compounds, metabolites, derivatives,  
 pharmaceutically acceptable salts, in combination with acids or bases,  
 and the like) and methods of using these compounds as antagonists of the  
 anti-apoptotic effects of Bcl-2 family member proteins (e.g., Bcl-2,  
 Bcl-X.sub.L, and the like). The present invention also provides  
 compositions comprising gossypol compounds and optionally one or more  
 additional therapeutic agents (e.g., anticancer/chemotherapeutic  
 agents). The present invention also provides methods for treating  
 diseases and pathologies (e.g., neoplastic diseases) comprising  
 administering a composition comprising gossypol compounds and optionally  
 one or more additional therapeutic agents (e.g.,  
 anticancer/chemotherapeutic agents) and/or techniques (e.g.,  
 radiation therapies, surgical interventions, and the like) to a

subject or in vitro cells, tissues, and organs.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 59 OF 59 USPATFULL on STN  
AN 90:79881 USPATFULL  
TI Stable lyophilized form of (S)-(+)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione and solutions thereof  
IN Palepu, Nagesh R., Franklin County, OH, United States  
Martin, Joyce W., Franklin County, OH, United States  
PA Erbamont Inc., Dublin, OH, United States (U.S. corporation)  
PI US 4963551 19901016  
AI US 1990-463844 19900112 (7)  
RLI Continuation of Ser. No. US 1987-136036, filed on 21 Dec 1987, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Bell, Mark L.; Assistant Examiner: Brunsman, David M.  
LREP Thompson, Hine and Flory  
CLMN Number of Claims: 15  
ECL Exemplary Claim: 1  
DRWN No Drawings  
LN.CNT 378  
AB The present invention is directed to a stable, rapidly soluble lyophilized injectable composition containing up to about 6% moisture and capable of being stored at room temperature comprising the hydrochloric or sulfate salt of a compound selected from the group consisting of (S)-(+)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione and (R)-(-)-bis-4,4'-(1-methyl-1,2-ethanediyl)2,6-piperazinedione; wherein said lyophilized composition is prepared from a bulk solution comprising from about 25 mg/mL to about 40 mg/mL of said compound dissolved in a hydrochloric acid or sulfuric acid; wherein the pH of said bulk solution is from about 1.0 to about 2.0. The invention is further directed to an isotonic solution which is formed upon reconstitution of the lyophilizate of the invention with a pharmaceutically acceptable diluent.

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	313.09	313.30
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.20	-3.20

FILE 'CAPLUS' ENTERED AT 17:12:08 ON 15 AUG 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Aug 2008 VOL 149 ISS 8  
FILE LAST UPDATED: 14 Aug 2008 (20080814/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s Hofland Kenneth/AU  
L13 2 HOFLAND KENNETH/AU

=> dis l13 1-2 bib abs

L13 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2005:1004605 CAPLUS  
DN 143:279366  
TI Cancer treatment with topoisomerase II inhibitor, a bis-dioxypiperazine and radiation  
IN Hofland, Kenneth; Sehested, Maxwell; Kristjansen, Paul; Thougard, Annemette; Jensen, Peter Buhl  
PA Topotarget A/S, Den.  
SO PCT Int. Appl., 28 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005084754	A2	20050915	WO 2005-IB670	20050302
	WO 2005084754	A3	20060526		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005219034	A1	20050915	AU 2005-219034	20050302
	CA 2557857	A1	20050915	CA 2005-2557857	20050302
	EP 1720612	A2	20061115	EP 2005-708755	20050302
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	JP 2007527428	T	20070927	JP 2007-501380	20050302
	US 20070185124	A1	20070809	US 2007-591847	20070109
PRAI	GB 2004-4675	A	20040302		
	WO 2005-IB670	W	20050302		
AB	The present invention relates to a method of treatment of a tumor cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in				



combination with a bis-dioxypiperazine, e.g. dexrazoxane, wherein said subject is further treated with radiation.

L13 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:307970 CAPLUS

DN 133:187729

TI Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex

AU Hofland, Kenneth; Petersen, Birgit O.; Falck, Jacob; Helin, Kristian; Jensen, Peter B.; Sehested, Maxwell

CS Laboratory and Finsen Centres, Rigshospitalet, Copenhagen, DK-2100, Den.

SO Clinical Cancer Research (2000), 6(4), 1488-1497

CODEN: CCREF4; ISSN: 1078-0432

PB American Association for Cancer Research

DT Journal

LA English

AB The transcription factor complex E2F-1/DP-1 regulates the G1-to-S-phase transition and was associated with sensitivity to the S-phase-specific anticancer agents camptothecin and etoposide, which poison DNA topoisomerase I and II, resp. To investigate the relationship between E2F-1 and drug sensitivity in detail, the authors established human osteosarcoma U-2OS-TA cells expressing full-length E2F-1/DP-1 under the control of a tetracycline-responsive promoter, designated UE1DP-1 cells. Topoisomerase I levels and activity as well as the number of camptothecin-induced DNA single- and double-strand breaks were unchanged in UE1DP-1/tc- cells with > 10-fold E2F-1/DP-1 overexpression. However, UE1DP-1/tc- cells were hypersensitive to camptothecin in both a clonogenic assay and 4 different apoptotic assays. This indicates that camptothecin-induced toxicity in this model is due to the activation of an E2F-1/DP-1-induced post-DNA damage pathway rather than an increase in the number of replication forks caused by the S-phase initiation. In contrast, topoisomerase II $\alpha$  levels (but not topoisomerase II $\beta$  levels), together with topoisomerase II $\alpha$  promoter activity, increased 2-3-fold in UE1DP-1/tc- cells. Furthermore, the number of etoposide-induced DNA single- and double-strand breaks increased in UE1DP-1/tc- cells together with a rise in clonogenic sensitivity to etoposide, but an equal apoptotic sensitivity to etoposide. The increase in topoisomerase II $\alpha$  promoter activity in UE1DP-1/tc- cells was shown to be due to S-phase initiation per se because it was blocked by ectopic expression of dominant neg. cyclin-dependent kinase 2. In conclusion, overexpression of E2F-1/DP-1 in U-2OS-TA cells is sufficient to increase clonogenic sensitivity to both topoisomerase I- and II-targeted anticancer drugs. However, the mechanism by which this occurs appears to be qual. different. The UE1DP-1 cell model may be used to elucidate post-DNA damage mechanisms of cell death induced by topoisomerase I-directed anticancer agents.

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s Sehested Maxwell/AU

L14 83 SEHESTED MAXWELL/AU

=> s l14 and topoisomerase

13765 TOPOISOMERASE

1840 TOPOISOMERASES

14064 TOPOISOMERASE

(TOPOISOMERASE OR TOPOISOMERASES)

L15 40 L14 AND TOPOISOMERASE

=> s l15 and dioxypiperazine

6 DIOXYPIPERAZINE

L16 2 L15 AND DIOXYPIPERAZINE

=> dis 116 1-2 bib abs

L16 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2005:1004605 CAPLUS  
DN 143:279366  
TI Cancer treatment with topoisomerase II inhibitor, a bis-dioxypiperazine and radiation  
IN Hofland, Kenneth; Sehested, Maxwell; Kristjansen, Paul; Thouggaard, Annemette; Jensen, Peter Buhl  
PA Topotarget A/S, Den.  
SO PCT Int. Appl., 28 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005084754	A2	20050915	WO 2005-IB670	20050302
	WO 2005084754	A3	20060526		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, BH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005219034	A1	20050915	AU 2005-219034	20050302
	CA 2557857	A1	20050915	CA 2005-2557857	20050302
	EP 1720612	A2	20061115	EP 2005-708755	20050302
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	JP 2007527428	T	20070927	JP 2007-501380	20050302
	US 20070185124	A1	20070809	US 2007-591847	20070109
PRAI	GB 2004-4675	A	20040302		
	WO 2005-IB670	W	20050302		

AB The present invention relates to a method of treatment of a tumor cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane, wherein said subject is further treated with radiation.

L16 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 1997:556108 CAPLUS  
DN 127:145175  
OREF 127:27889a  
TI Topoisomerase II poison and bis-dioxypiperazine derivative combination therapy  
IN Jensen, Peter Buhl; Sehested, Maxwell  
PA Jensen, Peter Buhl, Den.; Sehested, Maxwell  
SO PCT Int. Appl., 52 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9725044	A1	19970717	WO 1997-DK13	19970110
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2242406	A1	19970717	CA 1997-2242406	19970110
	AU 9713677	A	19970801	AU 1997-13677	19970110
	EP 874630	A1	19981104	EP 1997-900205	19970110
	EP 874630	B1	20030820		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 247468	T	20030915	AT 1997-900205	19970110
	PT 874630	T	20040130	PT 1997-900205	19970110
	ES 2205164	T3	20040501	ES 1997-900205	19970110
	US 6265385	B1	20010724	US 1999-101499	19990308
PRAI	DK 1996-22	A	19960111		
	US 1996-603105	A	19960220		
	WO 1997-DK13	W	19970110		

AB The present invention relates to a method for selectively killing tumor or metastatic cells within a defined compartment of the organism of a large mammal, in particular a human, said method comprising administering to a mammal an effective tumor- or metastasis-killing amount of a topoisomerase II poison except doxorubicin, and protecting non-tumorous tissue of the mammal against the toxic action of the topoisomerase II poison by administration of a bis-dioxypiperazine compound. In particular, the invention relates to a pharmaceutical kit for selectively killing tumor or metastatic cells within the central nervous system of a large mammal, in particular a human, said kit comprising: a) a dosage unit of a bis-dioxypiperazine and a pharmaceutically acceptable carrier, and b) a dosage unit of topoisomerase II poisons except doxorubicin and a pharmaceutically acceptable carrier.

=> s Kristjansen Paul/AU  
L17 1 KRISTJANSEN PAUL/AU

=> dis 117 bib abs

L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2005:1004605 CAPLUS  
DN 143:279366  
TI Cancer treatment with topoisomerase II inhibitor, a bis-dioxypiperazine and radiation  
IN Hofland, Kenneth; Sehested, Maxwell; Kristjansen, Paul; Thougard, Annemette; Jensen, Peter Buhl  
PA Topotarget A/S, Den.  
SO PCT Int. Appl., 28 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005084754	A2	20050915	WO 2005-IB670	20050302

WO 2005084754 A3 20060526  
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
AU 2005219034 A1 20050915 AU 2005-219034 20050302  
CA 2557857 A1 20050915 CA 2005-2557857 20050302  
EP 1720612 A2 20061115 EP 2005-708755 20050302  
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU  
JP 2007527428 T 20070927 JP 2007-501380 20050302  
US 20070185124 A1 20070809 US 2007-591847 20070109  
PRAI GB 2004-4675 A 20040302  
WO 2005-IB670 W 20050302

AB The present invention relates to a method of treatment of a tumor cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane, wherein said subject is further treated with radiation.

=> s Thougard Annemette/AU  
L18 3 THOUGAARD ANNEMETTE/AU

=> dis 118 1-3 bib abs

L18 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:510771 CAPLUS  
DN 147:268549  
TI The histone deacetylase inhibitor PXD101 synergizes with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo  
AU Tumber, Anthony; Collins, Laura S.; Petersen, Kamille Dumong; Thougard, Annemette; Christiansen, Sanne J.; Dejligbjerg, Marielle; Jensen, Peter Buhl; Sehested, Maxwell; Ritchie, James W. A.  
CS TopoTarget UK LTD, Abingdon, OX14 4RY, UK  
SO Cancer Chemotherapy and Pharmacology (2007), 60(2), 275-283  
CODEN: CCPHDZ; ISSN: 0344-5704  
PB Springer  
DT Journal  
LA English  
AB Histone deacetylase inhibitors (HDACi) inhibit the growth of cancer cells, and combinations of HDACi with established chemotherapeutics can lead to synergistic effects. We have investigated effects of PXD101 (HDACi in phase II clin. trials) in combination with 5-fluorouracil, on tumor cell proliferation and apoptosis both in vitro and in vivo. HCT116 cells were studied using proliferation and clonogenic assays. Synergistic inhibition of proliferation and clonogenicity was determined by incubation with PXD101 and 5-fluorouracil, and anal. using CalcuSyn software. The effect of combining PXD101 and 5-fluorouracil on apoptosis was examined in vitro using PARP-cleavage and TUNEL. Finally, the effectiveness of combining PXD101 and 5-fluorouracil in vivo was tested using both HT-29 and HCT116 xenograft models. Synergistic inhibition of proliferation and clonogenicity was obtained when HCT116 cells were incubated with PXD101

and 5-fluorouracil. 5-fluorouracil combined with PXD101 also increased DNA fragmentation and PARP cleavage in HCT116 cells. Incubation with PXD101 down regulated thymidylate synthase expression in HCT116 cells. In vivo studies, using mouse HT29 and HCT116 xenograft models, showed improved redns. in tumor volume compared to single compound, when PXD101 and 5-fluorouracil were combined. PXD101 and 5-fluorouracil synergistically combine in their antitumor effects against colon cancer cells in vitro and show enhanced activity when combined in vivo. Based on the results presented herein, a rationale for the use of PXD101 and 5-fluorouracil in combination in the clinic has been demonstrated.

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:842431 CAPLUS

DN 145:284390

TI Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies

AU Qian, Xiaozhong; LaRochelle, William J.; Ara, Gulshan; Wu, Frank; Petersen, Kamille Dumong; Thougard, Annemette; Sehested, Maxwell; Lichenstein, Henri S.; Jeffers, Michael

CS CuraGen Corporation, Branford, CT, 06405, USA

SO Molecular Cancer Therapeutics (2006), 5(8), 2086-2095  
CODEN: MCTOCF; ISSN: 1535-7163

PB American Association for Cancer Research

DT Journal

LA English

AB Histone deacetylase inhibitors represent a promising new class of anticancer agents. In the current investigation, we examined the activity of PXD101, a potent histone deacetylase inhibitor, used alone or in combination with clin. relevant chemotherapeutics (docetaxel, paclitaxel, and carboplatin), in preclin. in vitro and in vivo models of ovarian cancer. In vitro activity was examined in ovarian cancer and multidrug-resistant cell lines grown in monolayer culture, and in primary clin. ovarian cancer specimens grown in three-dimensional organoid culture. PXD101 was found to inhibit in vitro cancer cell growth at sub-to low micromolar IC50 potency, exhibited synergistic activity when used in combination with relevant chemotherapeutics, and effectively inhibited the growth of multidrug-resistant cells. In vivo, PXD101 displayed single-agent antitumor activity on human A2780 ovarian cancer s.c. xenografts which was enhanced via combination therapy with carboplatin. In support of these findings, PXD101 was shown to increase the acetylation of  $\alpha$ -tubulin induced by docetaxel and the phosphorylation of H2AX induced by carboplatin. Taken together, these results support the clin. evaluation of PXD101 used alone or in combination therapy for the treatment of ovarian cancer.

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1004605 CAPLUS

DN 143:279366

TI Cancer treatment with topoisomerase II inhibitor, a bis-dioxypiperazine and radiation

IN Hofland, Kenneth; Sehested, Maxwell; Kristjansen, Paul; Thougard, Annemette; Jensen, Peter Buhl

PA Topotarget A/S, Den.

SO PCT Int. Appl., 28 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005084754	A2	20050915	WO 2005-IB670	20050302
	WO 2005084754	A3	20060526		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005219034	A1	20050915	AU 2005-219034	20050302
	CA 2557857	A1	20050915	CA 2005-2557857	20050302
	EP 1720612	A2	20061115	EP 2005-708755	20050302
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	JP 2007527428	T	20070927	JP 2007-501380	20050302
	US 20070185124	A1	20070809	US 2007-591847	20070109
PRAI	GB 2004-4675	A	20040302		
	WO 2005-IB670	W	20050302		

AB The present invention relates to a method of treatment of a tumor cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane, wherein said subject is further treated with radiation.

=> s Jensen Peter Buhl/AU  
L19 43 JENSEN PETER BUHL/AU

=> s 119 and topoisomerase  
13765 TOPOISOMERASE  
1840 TOPOISOMERASES  
14064 TOPOISOMERASE  
(TOPOISOMERASE OR TOPOISOMERASES)  
L20 23 L19 AND TOPOISOMERASE

=> s 120 and dioxypiperazine  
6 DIOXYPIPERAZINE  
L21 2 L20 AND DIOXYPIPERAZINE

=> dis 121 1-2 bib abs

L21 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2005:1004605 CAPLUS  
DN 143:279366  
TI Cancer treatment with topoisomerase II inhibitor, a bis-dioxypiperazine and radiation  
IN Hofland, Kenneth; Sehested, Maxwell; Kristjansen, Paul; Thougard, Annemette; Jensen, Peter Buhl  
PA Topotarget A/S, Den.  
SO PCT Int. Appl., 28 pp.  
CODEN: PIXXD2  
DT Patent  
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005084754	A2	20050915	WO 2005-IB670	20050302
	WO 2005084754	A3	20060526		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005219034	A1	20050915	AU 2005-219034	20050302
	CA 2557857	A1	20050915	CA 2005-2557857	20050302
	EP 1720612	A2	20061115	EP 2005-708755	20050302
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	JP 2007527428	T	20070927	JP 2007-501380	20050302
	US 20070185124	A1	20070809	US 2007-591847	20070109
PRAI	GB 2004-4675	A	20040302		
	WO 2005-IB670	W	20050302		

AB The present invention relates to a method of treatment of a tumor cell which comprises administering to a subject in need of treatment an effective amount of a topoisomerase-II poison, e.g. etoposide, in combination with a bis-dioxypiperazine, e.g. dexrazoxane, wherein said subject is further treated with radiation.

L21 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:556108 CAPLUS

DN 127:145175

OREF 127:27889a

TI Topoisomerase II poison and bis-dioxypiperazine derivative combination therapy

IN Jensen, Peter Buhl; Sehested, Maxwell

PA Jensen, Peter Buhl, Den.; Sehested, Maxwell

SO PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9725044	A1	19970717	WO 1997-DK13	19970110
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	CA 2242406	A1	19970717	CA 1997-2242406	19970110
	AU 9713677	A	19970801	AU 1997-13677	19970110
	EP 874630	A1	19981104	EP 1997-900205	19970110
	EP 874630	B1	20030820		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, FI

AT 247468	T	20030915	AT 1997-900205	19970110
PT 874630	T	20040130	PT 1997-900205	19970110
ES 2205164	T3	20040501	ES 1997-900205	19970110
US 6265385	B1	20010724	US 1999-101499	19990308
PRAI DK 1996-22	A	19960111		
US 1996-603105	A	19960220		
WO 1997-DK13	W	19970110		

AB The present invention relates to a method for selectively killing tumor or metastatic cells within a defined compartment of the organism of a large mammal, in particular a human, said method comprising administering to a mammal an effective tumor- or metastasis-killing amount of a topoisomerase II poison except doxorubicin, and protecting non-tumorous tissue of the mammal against the toxic action of the topoisomerase II poison by administration of a bis-dioxypiperazine compound. In particular, the invention relates to a pharmaceutical kit for selectively killing tumor or metastatic cells within the central nervous system of a large mammal, in particular a human, said kit comprising: a) a dosage unit of a bis-dioxypiperazine and a pharmaceutically acceptable carrier, and b) a dosage unit of topoisomerase II poisons except doxorubicin and a pharmaceutically acceptable carrier.

=> dis hist

(FILE 'HOME' ENTERED AT 17:03:06 ON 15 AUG 2008)

FILE 'MEDLINE, BIOSIS, APOLLIT, BABS, CAPLUS, CBNB, CIN, COMPENDEX, DISSABS, EMA, IFIPAT, NTIS, PASCAL, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPATOLD, USPAT2, WPIFV, WPINDEX, WSCA, WTEXTILES, EMBASE' ENTERED AT 17:03:41 ON 15 AUG 2008

L1	0	S	TOPOISOMERSE(A)II(A)POISON
L2	1540	S	TOPOISOMERASE(A)II(A)POISON
L3	21	S	L2 AND (DIOXYPIPERAZINE OR PIPERAZINEDIONE)
L4	1	S	PIPERAZINEDIONE(W)RADIATION
L5	5385	S	PIPERAZINEDIONE
L6	786	S	L5 AND RADIATION
L7	455	S	L6 AND (ANTI(A)TUMOR)
L8	433	S	L7 AND TOXICITY
L9	394	S	L8 AND BIS
L10	6550	S	(BIS AND ETHANEDIYL)
L11	67	S	L8 AND (BIS AND ETHANEDIYL)
L12	59	S	L11 AND IONIZING

FILE 'CAPLUS' ENTERED AT 17:12:08 ON 15 AUG 2008

L13	2	S	HOFLAND KENNETH/AU
L14	83	S	SEHESTED MAXWELL/AU
L15	40	S	L14 AND TOPOISOMERASE
L16	2	S	L15 AND DIOXYPIPERAZINE
L17	1	S	KRISTJANSEN PAUL/AU
L18	3	S	THOUGAARD ANNEMETTE/AU
L19	43	S	JENSEN PETER BUHL/AU
L20	23	S	L19 AND TOPOISOMERASE
L21	2	S	L20 AND DIOXYPIPERAZINE

=>